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A proposal has been developed by the Agricultural Chemical Safety Assessment (ACSA) Techni-
cal Committee of the ILSI Health and Environmental Sciences Institute (HESI) for an improved
approach to assessing the safety of crop protection chemicals. The goal is to ensure that studies
are scientifically appropriate and necessary without being redundant, and that tests emphasize
toxicological endpoints and exposure durations that are relevant for risk assessment. The ACSA
Systemic Toxicity Task Force proposes an approach to systemic toxicity testing as one part of the
overall assessment of a compound’s potential to cause adverse effects on health. The approach is
designed to provide more relevant data for deriving reference doses for shorter time periods of
human exposure, and includes fewer studies for deriving longer term reference doses—that is,
neither a 12-month dog study nor a mouse carcinogenicity study is recommended. All available
data, including toxicokinetics and metabolism data and life stages information, are taken into
account. The proposed tiered testing approach has the potential to provide new risk assessment
information for shorter human exposure durations while reducing the number of animals used
and without compromising the sensitivity of the determination of longer term reference doses.
Keywords Agricultural Chemicals, Health-Based Guidance Values, Risk Assessment, SABRE
Database, Systemic Toxicity Testing, Tiered Testing
INTRODUCTION
The ILSI Health and Environmental Sciences Institute
(HESI) formed the Agricultural Chemical Safety Assessment
(ACSA) Technical Committee in the year 2000 to design a toxi-
city testing scheme that would incorporate current understanding
of pesticide toxicology and exposure and recognize the speci-
ficity of agricultural products. The purpose of and background
for the ACSA project are described in detail in the companion
paper by Carmichael et al. (2006).
As the proposed tiered testing approach for agricultural chem-
ical safety assessment evolved, the ACSA Technical Com-
mittee and its task forces (Barton et al., 2006; Carmichael
et al., 2006; Cooper et al., 2006) worked toward the following
objectives:
• Provide information that can be applied to a range of
relevant human exposure situations.
• Characterize effects that have the potential to dam-
age human health at exposure levels approximating
those that might be encountered in the use of these
compounds.
• Avoid high doses that cause unnecessary public con-
cern (e.g., safety assessments should focus on doses
that are relevant to realistic human exposures while
maintaining adequate power for the experimental stud-
ies to detect toxicity).
• Use the minimum number of animals necessary to pro-
duce a thorough safety assessment of the chemicals of
interest.
• Inflict the minimum amount of distress on animals.
• Minimize excessive and unnecessary use of resources
by regulatory authorities and industry which could be
used to address other issues of concern.
• Increase both the efficiency and relevance of the current
safety assessment process.
Definition of the Scope of Systemic Toxicity
The goal of the Systemic Toxicity Task Force (the Task Force)
of the ACSA Technical Committee was to develop a hierarchy of
study types, endpoints, and triggers for a decision tree for other
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toxicity endpoints, such as neurotoxicity, carcinogenicity, and
chronic toxicity. The Task Force defined “systemic toxicity” for
the purposes of the HESI project as the potential adverse effects
of agricultural chemicals on “young adults.” In this context, sys-
temic toxicity includes general toxicology and specific effects
on the nervous system, the immune system, and the endocrine
system; genetic toxicology; carcinogenicity; and irritancy and
sensitization.
The assessment of systemic toxicity in “young adults” is often
the first step in the overall assessment of a compound’s poten-
tial to cause adverse effects on health. The findings in young
adults are then taken into account during the assessment of the
compound during different life stages, including reproduction,
development, adolescence, and the elderly. The process for as-
sessing the effects of agricultural chemicals on these life stages
is the subject of the companion paper by the ACSA Life Stages
Task Force (Cooper et al., 2006). A complete assessment can
be made only by taking into account all of the data generated
in the overall assessment. Modes of action may be revealed in
the assessment of systemic toxicity that will also reveal them-
selves in the assessment of different life stages. The assessments
are underpinned by knowledge of toxicokinetics, from which
internal, rather than externally applied, dose can be related to
effects. The ACSA ADME Task Force has reviewed the assess-
ment of toxicokinetics data (Barton et al., 2006). The work of
all three ACSA Task Forces is complementary and should be
considered together. A key aspect of the overall approach de-
scribed here is to provide data that shed light on the shape of
the dose-response curve, rather than emphasizing effects that
may occur only at high doses. Reference doses are usually set
on the critical effects, that is, the first effects occurring as the
dose level is increased, although such dose levels are usually
discovered by reducing the dose level until effects are no longer
observed.
ASSESSMENT OF THE CURRENT TESTING STRATEGY
Comparison of the Agricultural Chemical Testing Strategy
with Safety Assessment Strategies for Other Chemicals
The Task Force reviewed the way in which food additives,
biocides, and pharmaceuticals are assessed by regulatory author-
ities in Europe and the United States. Each includes the concept
that the studies that are done should reflect the toxicity of the
chemical and its use profile.
The factors that are taken into account include:
• Exposure level, frequency, and duration.
• Level of toxicological concern about the chemical.
Each regulatory agency has a declared intention to limit the
number of animals used in assessing the potential hazards of a
chemical.
The testing schemes for food additives, biocides, and phar-
maceuticals differ from the current agricultural chemical testing
scheme in that they allow more opportunity for the use pro-
file, the resulting exposure, and the toxicological profile of the
chemical to influence the design of the evaluation program.
Human Exposure Durations Required
for Risk Assessments
The range of required risk assessments has increased in recent
years as knowledge has grown concerning the range of exposures
to which humans may be subjected. Initially, the assessment of
agricultural chemicals focused on continuous dietary exposure,
which gave rise to the concept of the acceptable daily intake
(ADI) for a lifetime. However, it is now recognized that there is
a much broader range of exposure durations that must be con-
sidered, including exposures of workers applying agricultural
chemicals, exposures of bystanders, home use, and short-term
exposures in the diet. The Task Force identified the following
human exposure durations for which risk assessments may be
required:
• One day.
• Two to 28 days.
• One to 6 months.
• Greater than 6 months.
The Task Force considered whether there should be further divi-
sion of the duration of exposure of “greater than 6 months,” bear-
ing in mind that this exposure duration ranges from 7 months of
exposure to a lifetime’s exposure, and that it would, therefore,
be equivalent to the traditional lifetime ADI. The Task Force
concluded that there would be relatively few occasions when a
reference dose derived for a lifetime would be excessively con-
servative for 7 months exposure duration. Such situations would
likely become apparent as the chemical properties are examined
and the testing program progresses.
Exposure can occur from a variety of sources, including ex-
posure to the concentrated compound during manufacture, trans-
port, and dispensing; exposure to more dilute compound during
the application of the compound; and exposure to residues in diet
and drinking water. In addition, intermittent exposure should be
considered. The Task Force created a data set that could provide
risk assessors, who are acting to safeguard the health of those
using agricultural chemicals or who may be exposed to them in
diet, drinking water, or as bystanders, with information to allow
the assessment of the impact of a wide range of potential human
exposures.
Matching Current Studies with Exposure Durations
for Risk Assessments
The current testing strategy employed by regulatory agencies
around the world is primarily focused on two scenarios:
• Single exposure to large amounts of the undiluted
substance.
• Prolonged exposure to the substance in the diet.
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In addition, there are two areas of concern for regulatory author-
ities that have received attention in recent years and for which
new study designs have been or are under development:
• Medium-term exposure during mixing/loading by
operators.
• Single-day dietary exposure.
The acute toxicity package of oral, dermal, inhalation studies,
skin and eye irritation, and skin sensitization is designed to as-
sess the effects of single exposures to the undiluted substance.
The acute toxicity studies use death or severe toxicity as an
endpoint, and the data are applied primarily for classification
into various hazard categories for transport and general handling
purposes.
The effect of prolonged exposure in the diet is assessed by
the current program of studies that starts with a 28-day rat study.
Note that the 28-day rat study is often viewed as a dose-setting
study, and is not always submitted to regulatory authorities. The
program of studies then proceeds to the 90-day rat study and
the chronic rat study, which usually includes an assessment of
carcinogenicity. In addition, a parallel series of studies is done
in the dog (90-day and 1-year). A mouse carcinogenicity study
is performed. Data are also generated to explore the effect of the
chemical on reproduction and development. These studies have
been considered by the ACSA Life Stages Task Force (Cooper
et al., 2006). The data from these studies are used to identify
and characterize the hazards of the substance, that is, what ef-
fects it causes and at which dose levels. This information is used
in risk assessments. Over the three decades since this process
was introduced, it has become apparent that it no longer meets
all the needs of risk assessors who are acting to safeguard the
health of those using agricultural chemicals or who may be ex-
posed to them in diet, drinking water, or as bystanders. Concerns
about the effects of agricultural chemicals have broadened from
single, intermittent, and prolonged dietary exposure, to include
inadvertent exposure in drinking water and application of chem-
icals in and around the home and other buildings. Despite these
concerns, risk assessors must use the database provided by the
current testing strategy and devise ways to extrapolate the data
to meet their needs. A core principle of this project is to start
with the needs of risk assessors and design a series of studies to
meet those needs.
Focusing on risk assessment as the purpose for toxicology
studies calls into question whether all the studies that are cur-
rently conducted are actually needed. The purpose of hazard
characterization is to identify the likely adverse health effects,
and provide a dose that, if not exceeded, would prevent these ad-
verse health effects from occurring. This reference dose (RfD)
can then be compared to the actual or projected exposure through
the process of risk assessment. In most cases, when the database
is complete using the large number of animals mandated by the
test guidelines, only one study is used to set the RfD for each
risk assessment. The question then arises: Would it have been
possible to eliminate the studies which were not used for risk
assessment and still protect human health?
Through the use of improved, expanded, and better designed
studies, the Task Force proposes that it is possible to limit the
number of animal studies required while still identifying the
potential human health hazards of a chemical.
ANALYSIS OF THE USE OF THE CURRENT DATABASE
The current program for the assessment of agricultural chem-
icals has been in place for more than the last quarter of the 20th
century. Although it has evolved somewhat during that time, its
core has remained essentially unchanged. Hundreds of chemi-
cals have been evaluated, which together form a rich database on
the toxicity of agricultural chemicals. The Task Force acknowl-
edges that any changes to the current assessment program must
necessarily be based on sound scientific data. Consequently, a
representative cross section of the large data set on the toxicity
of agricultural chemicals was selected as a reference point for
the Task Force. This data set was examined to determine which
studies have been used most often to set the key reference RfDs
for chemicals. The data guided the Task Force in the selection
of study types to be used in the future and the identification of
study types that may not be necessary. To achieve this objective,
the Task Force commissioned the SABRE (Safety Assessment
by Refined Experimentation) database described next.
Description of the SABRE Database and Other
Data Sources
Initially, two to six chemicals from each class of pesti-
cide (i.e., organophosphates, carbamates, pyrethroids, etc.) were
randomly selected from a list of chemicals whose toxicology
database had been evaluated by the Hazard Identification As-
sessment Review Committee (HIARC) of the Health Effects
Division (HED), Office of Pesticide Programs (OPP), U.S. En-
vironmental Protection Agency (EPA). During the U.S. EPA
evaluation process, various toxicity endpoints (such as acute and
chronic RfDs, incidental oral or dermal endpoints) were selected
for risk assessment purposes. For each pesticide, the rationale for
the toxicity endpoints and the conclusion of the peer review were
recorded in a HIARC document, which served as a good starting
point for data mining. The document contained all the necessary
record keeping information in the OPP database (i.e., PC code
and MRID number). With the PC code, the appropriate Reg-
istration Eligibility Document (RED) or Registration Standard
could be easily accessed. In a RED, a summarized section of the
toxicity for a pesticide is excerpted from the Toxicology Chapter
prepared by HED. From the Toxicology Chapter, the individual
study data evaluation report (DER) could be obtained. Within
the Toxicology Chapter, a toxicology profile of a pesticide was
always prepared and included. The toxicology profile of a pes-
ticide contained brief summaries of essentially all the relevant
toxicity studies used to establish toxicity endpoints. Informa-
tion included date of the study, dose levels tested, no-observed-
adverse-effect level (NOAEL), lowest-observed-adverse-effect
A TIERED APPROACH TO SYSTEMIC TOXICITY TESTING 41
level (LOAEL), and the effects seen at the LOAEL. The tox-
icology profile was a crucial source for data mining. For the
selected pesticide, another database, Toxicology Onliner, was
also searched for additional information on older studies, if nec-
essary. Under some circumstances, the HIARC report, Toxicol-
ogy Chapter, and the toxicology profile did not provide a clear
description of the effects; the DER of an individual study was
always consulted.
For tumor incidences of carcinogenic pesticides, the Cancer
Peer Review Document was consulted. For classification and
the mode of pesticidal action for each pesticide, The Pesticide
Book (Ware, 2000) was consulted.
The relevant toxicology information of each selected pesti-
cide was extracted from the toxicology profile, HIARC report,
Toxicology Onliner, DER, and The Pesticide Book (Ware, 2000)
to be entered into the data spreadsheet. The information con-
sisted of the summarized results of subchronic oral, dermal,
and/or inhalation toxicity studies in rats and dogs; chronic toxi-
city studies in rats and dogs; carcinogenicity studies in rats and
mice; developmental toxicity studies in rats and rabbits; multi-
generation studies in rats; acute and subchronic neurotoxicity
studies in rats; and any pertinent special studies. The LOAEL
and NOAEL used to establish acute and chronic RfDs, tumor
incidence, any sex difference in response to the chemical, tar-
get organ of toxicity, and the mode of toxicity (if demonstrated)
were also entered into the database. In addition, the values for
the acute and chronic RfDs were included. Toxicity information
on 65 pesticides was entered into the database.
Interrogation of SABRE and Other Databases
The SABRE database, which was built specifically to assist
the analyses presented here, allowed a unique series of questions
to be answered. Of the 65 chemicals held in SABRE, 28 pos-
sessed appropriate data (from the core types of study required)
for the current systemic toxicity testing paradigm for agricultural
chemicals.
These core studies are the 90-day studies in the rat and dog,
the combined chronic and carcinogenicity study in the rat, the
1-year study in the dog, and the carcinogenicity study in the
mouse.
Using this data set, it was possible to address the following
key questions concerning the study durations and test species
currently used:
• The frequency with which the rat or the dog is used in
regulation (specifically in setting the chronic RfD for
a chemical).
• The identity of study types (durations and species) that
are not used or that provide data that can be obtained
from studies of a shorter duration or in a different
species.
In addressing these questions using the SABRE database, a
direct comparison may be drawn between the human durations
relevant to risk assessment and the utility of current studies in
risk assessment. Most importantly, the analyses were used to
differentiate between those study types that should be retained
and developed for future use, and those that should not.
The Frequency with which the Rat or the Dog Is Used
in Setting the Chronic RfD for a Chemical
The purpose of using two species is to increase the proba-
bility of detecting an effect that would be potentially adverse
to humans. The second species is used to cover the possibility
that the rat may not be susceptible to an effect of a compound
to which humans are susceptible, or the rat may be significantly
less sensitive than humans to an effect. The use of a second
species that is phylogenetically removed from the rat increases
the likelihood that one or the other of the species will be at least
as sensitive and/or susceptible as humans. In Table 1, data for
28 chemicals are summarized. These are the chemicals from the
SABRE database for which there is a complete data set from 90-
day rat, 90-day dog, 24-month rat, and 1-year dog studies. The
outcome of the key studies is provided, as is a brief description of
the critical toxicity endpoints and the species used in risk assess-
ment to set the chronic RfD for each chemical. The following
conclusions may be drawn from analysis of the representative
set of chemicals drawn from the sources cited already:
• For this set of chemicals, 14 out of 28 (50%) are reg-
ulated on the outcome of studies in the dog. Twelve
(43%) of these chemicals showed increased sensitivity
to the chemical—that is, the same effects were seen
but at lower doses than in the rat. Two (7%) showed
a different susceptibility to the chemical—that is, the
chemical caused different effects in the dog, which also
had a lower NOAEL than the overall NOAEL in the rat
derived from different effects. For one, the NOAEL
was very high in both rat and dog, and the rat NOAEL
would be adequately protective of the effect seen in
the dog. For the other, the rat was more sensitive than
the dog (at 90 days), and the rat NOAEL would again
be adequately protective of the effect seen in the dog.
These chemicals are identified in Table 1 by having
either “sens” (sensitivity, same effect, lower dose) or
“susc” (susceptibility, different effect) in the final col-
umn if the dog is the species setting the chronic RfD.
The Identity of Study Types Not Used in Risk Assessment
Studies in the Rat and the Dog. In comparing the outcome of
studies of different duration in the rat, the relationship between
the respective NOAELs can be variable. However, the NOAEL
from the 90-day study is generally higher than the NOAEL in
the 2-year study for the same toxicity endpoint, indicating that,
for this species, the NOAEL can decrease with increasing period
of exposure. For the dog, the quantitative outcomes in 90-day
and 1-year studies are closer. Table 2 summarizes the data for
chemicals for which dog NOAELs were lower in longer studies
(that is, the one-year NOAEL is lower by a greater than twofold
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TABLE 2
Chemicals for which dog NOAELs were lower in longer exposure studies (SABRE data)
Active ingredient
90-Day dog
NOAEL
(mg/kg/day)
1-Year dog
NOAEL
(mg/kg/day)
Species used in
setting the ADI
Ratio dog 90-day:
12-month NOAELs
Ratio rat 90-day:
24-month NOAELs
Acetochlor 10 2 Dog 5 8
Butylate 45 5 Dog 9 0.3
Hexaconazole 5 2 Dog 2.5 0.6
Tebuconazole 73 2.9 Dog 25 3
Lactofen 75 0.79 Dog 70 20
2,4-DB 8 <2.39 Rat 4 5
Iprodione 60 17.5 Rat 4 12
Propachlor 38 6.25 Rat 12 30
difference, excluding the three chemicals for which no NOAEL
was determined in the 90-day study). The data show that for the
27 chemicals for which there were both 90-day and 1-year dog
studies, in only 8 cases were the 1-year values lower. In three of
these cases, the chemicals were regulated on the outcome in the
rat as the most sensitive species, making data generated in the
dog redundant for the purpose of setting the chronic RfD.
A further analysis of the remaining five chemicals showing
lower 1-year dog NOAELs has been undertaken to study the po-
tential influence of dose selection on the outcome of the studies.
Table 3 shows LOAELs from the respective 90-day and 1-year
studies for these chemicals:
• For hexaconazole, the difference in outcome is
within threefold and confirmed by both NOAELs and
LOAELs.
• Two 1-year studies have been conducted for acetochlor
that give differing outcomes, with one of the studies
within twofold of the outcome of the 90-day study.
• The lower 1-year NOAELs for tebuconazole and
lactofen cannot be ascribed to dose selection artifacts.
The capability to produce lower NOAELs in studies of longer
duration could be a property of the chemical. Rat 90-day and
TABLE 3
Impact of dose selection on dog LOAELs in 90-day and 1-year
studies (SABRE data)
Active ingredient
90-Day dog
LOAEL
(mg/kg/day)
1-Year dog
LOAEL
(mg/kg/day)
Acetochlor 60 12/40
Butylate >45 20
Hexaconazole 25 10
Tebuconazole 352 4.4
Lactofen 250 4
24-month data were compared to determine if this reduction
in NOAEL with increasing duration was also seen in the rat
(Table 2). Five of the eight chemicals have a similar ratio of
NOAELs between the longer and shorter term studies for both
species. For hexaconazole, the NOAELs for all four studies are
within a range of 2–5 mg/kg (rat 90-day: 3 mg/kg; rat 24-month:
4.7 mg/kg; dog 90-day: 5 mg/kg; and dog 12-month: 2 mg/kg),
which suggests that the variations may be caused by dose set-
ting. For tebuconazole, the dog 90-day NOAEL is considerably
higher than the other three NOAELs (rat 90-day: 9 mg/kg; rat
24-month: 5 mg/kg; dog 90-day: 73 mg/kg; and dog 12-month:
2.9 mg/kg). Butylate is difficult to understand, with the dog 12-
month NOAEL being considerably lower than the other three
NOAELs (rat 90-day: 32 mg/kg; rat 24-month: 100 mg/kg; dog
90-day: 45 mg/kg; and dog 12-month: 5 mg/kg), although the
LOAEL is 20 mg/kg.
Further analyses of the use of the dog and the optimum study
duration are described in this paper (see Refinement of the Pro-
posal: Role of the Second Species).
Studies of Carcinogenicity in the Mouse. In the data set
(shown in Table 5), there was one chemical for which 2-year rat
and mouse carcinogenicity studies were not available (chlorfe-
napyr), and there were four chemicals for which there was no
mouse carcinogenicity study. The chemicals were classified as
shown in Table 4, and they are identified as shown in Table 5.
Tumors were detected in the rat, with 13 of the 27 chemicals
remaining in the analysis (6 of these also induced tumors in the
mouse). An additional four chemicals induced mouse tumors in
the absence of findings in the rat; however, all but one of these
chemicals resulted in liver tumors. The modes of action for these
liver tumors were of questionable or no relevance to humans.
The Relationship between 28- and 90-Day Rat Data
Apart from a study carried out by the European Crop Protec-
tion Association (ECPA, 1999), there are few data on the rela-
tionship between the no-observed-effect levels (NOELs) in the
rat for study durations of 28 days and 90 days. Twenty-eight-day
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TABLE 4
Presence of tumors in studies in the SABRE database
Classification Identifier Number (%)
No tumors in rat or mouse N 10 (37%)
Liver tumors in mouse only ML 3 (17%)
Tumors other than liver
tumors in mouse only
MO 1 (4%)
Tumors only in rat R 7 (26%)
Tumors in both rat and
mouse
RM 6 (22%)
studies are commonly performed for dose-setting purposes for
90-day studies, and often do not include a full range of obser-
vations. Group sizes may be five rather than 10. In addition, an
expectation that the NOAEL will be lower in the subsequent 90-
day study will often cause the study director to choose a set of
dose levels lower than the dose levels used in the 28-day study.
It is common, for instance, to divide all the dose levels used in
the 28-day study by a factor of 2 or 3 when moving to the 90-day
study. Therefore, it is difficult to relate the results of these stud-
ies to their respective 90-day studies. Even so, the ECPA data
suggest that a factor of three would be adequate to extrapolate
between a 28-day rat and a 90-day rat study (Figure 1).
Summary of Analysis of the SABRE Database
In summary, analysis of the SABRE database indicates that:
• The rat and the dog can respond with a differential
sensitivity—that is, the same effects occur but at dif-
ferent dose levels—and less commonly with a different
susceptibility—that is, different effects occur—to the
same chemical. Both species should be retained as test
species for evaluating the systemic toxicity of agricul-
tural chemicals.
• Longer duration studies (1 year) in the dog do not result
in appreciably lower NOAELs or identify new effects
for the majority of chemicals when compared to the
shorter duration study (90 day) in this species (20 out
of 28 cases). This may be because the difference in
the proportion of the lifespan in the dog between 90
days and 1 year (2.5% and 10%, assuming a 10-year
lifespan) is relatively small when compared to a 90-
day rat study and a 24-month rat study (10% and 80%,
assuming a 2.5-year lifespan). However, when there is a
decrease in NOAEL between the 90-day and 12-month
dog studies, there is a decrease in NOAEL in the rat
between the 90-day and 24-month NOAELs in 5 out of
8 cases.
• The additional information provided by the mouse car-
cinogenicity study is of very limited additional value
in risk assessment.
DEVELOPMENT OF A TIERED APPROACH
Requirements and Challenges for the Development
of a Tiered Approach
Safety assessment of agricultural chemicals has, as its goal,
the facilitation of risk assessments for consumers, operators,
bystanders, residential uses, and others by identifying potential
adverse health effects. These effects must be characterized in
terms of variation of dose, duration of exposure, and route of
exposure. It should then be possible to derive a human expo-
sure level that should not be exceeded for a particular exposure
situation.
The challenge taken on by the Task Force was to improve
the ability of the data set to provide relevant information for
the variety of risk assessments required, while at the same time
reducing the number of animals needed for testing.
The Task Force developed a series of studies that achieves
the following:
• The series of studies provides data of direct relevance
for a range of less-than-lifetime durations of human
exposure that have been defined as being required for
risk assessments.
• The series allows for extrapolation from route to route
by utilizing ADME and a limited number of studies by
the dermal and inhalation routes.
• The series includes studies of short duration and “re-
covery periods” that can provide information of rele-
vance to intermittent exposures.
• The series covers a range of specific toxic effects that
can be assessed as appropriate to provide a more refined
evaluation of potential hazards.
The key elements of the series of studies are as follows:
• Studies are of appropriate duration to relate to human
exposure durations of relevance to risk assessment.
These studies incorporate a full set of toxicological
endpoints, whatever their duration. The shorter term
studies provide data for appropriate risk assessments
in their own right. This contrasts with the current test-
ing program in which shorter term studies are often
preliminary to longer term studies, and are designed
only to provide dose-setting information.
• Measurements of plasma levels of parent or appropriate
metabolites are taken for assessment of internal dose,
which aids in species-to-species and route-to-route ex-
trapolation.
• Recovery periods are included to aid with assessment
of intermittent exposures.
• Indicators for specific effects that lead to specialized
studies are included that will further characterize the
response if positive, but that will provide reasonable
assurance of the absence of concern if the indicators
are not triggered.
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TABLE 5
Tumor findings for 28 chemicals in the SABRE database
Active ingredient Chemical class Tumor findings
2,4-D Phenoxyacid No tumors
N
Acetochlor Acetanilide Nasal papillary adenomas in the rat; liver and lung tumors in the
mouse at ≥75 mg/kg/day
R
Atrazine Triazine Mammary tumors in the rat at 50 mg/kg/day
No mouse carcinogenicity
R
Butylate Carbamate Tumors in rat only
R
Carbaryl Carbamate Tumors in the rat at 350 mg/kg/day; liver and kidney tumors in the
mouse at 1249 mg/kg/day
RM
Cyprodinil Anilinopyrimidine No tumors
N
Diazinon Organophosphorothioate No tumors
No mouse carcinogenicity
N
Glufosinate ammonium Phosphinic acid analogue
of glutamic acid
No tumors
No mouse carcinogenicity
N
Hexaconazole Triazole Leydig cell tumors in rat at 47 mg/kg/day
R
Mevinphos Organophosphate Hepatocellular carcinomas in the rat at 0.6 mg/kg/day
No mouse study in database
N
Prallethrin Pyrethroid No tumors
N
Tebuconazole Triazole No tumors
Mouse—liver tumors at top dose of 279 mg/kg/day
ML
Triallate Thiocarbamate Tumors in rat; kidney tubular cell adenomas at 0.5 mg/kg/day
Mouse—hepatocellular carcinomas at 9 mg/kg/day
RM
Vinclozoline Dicarboximide Leydig-cell tumors in rat at top dose
Liver tumors in mouse at 1411 mg/kg/day
RM
Dicamba Dichlorobenzoate None
N
Dimethoate Organophosphate None
N
Chlorfenapyr Pyrrole None—no 2-year rat or mouse carcinogenicity studies in database
MCPA Dithiocarbamate Rat thyroid follicular cell tumors at high dose
R
Metolachlor Acetanilide Rat liver tumors at LOAEL
R
Benomyl Benzimidazole Mouse liver tumors at LDT (75 mg/kg/day)
ML
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TABLE 5
Tumor findings for 28 chemicals in the SABRE database (Continued)
Active ingredient Chemical class Tumor findings
Propachlor Acetanilide Rat ovarian and thyroid tumors and mouse liver tumors
RM
2,4-DB Phenoxyacid None
N
Fosetyl-AL Organophosphate Rat bladder tumors
R
Iprodione Dicarboximide Rat testicular tumors; mouse liver tumors
RM
Bifenthrin Pyrethroid Assorted tumors in the mouse
MO
Carboxin Oxathin No tumors
N
Dicofol Organochlorine No tumors
N
Lactofen Diphenyl ether Liver tumors in the mouse
ML
Note: See Table 4 for explanation of identifiers (N, ML, MO, R, and RM).
Basic Concept: Matching Duration of Study with
Duration of Human Exposure
The Task Force devised a set of studies which would provide
information for the following human exposure periods:
• One day.
• Two to 28 days.
• One to 6 months.
• Greater than 6 months.
Animal Study to Provide Data Relevant to 1-Day Human
Exposure. A single-dose study is proposed with full evalua-
tion at 24 hours and 7 days, with histology, clinical chemistry,
hematology and other specialized investigations that may be in-
dicated by structure activity or information from other studies.
FIG. 1. Ratio of NOELs and LOELs from ECPA data (ECPA,
1999).
Animal Study to Provide Data Relevant to 2 to 28 Days (2 to
7 Days and 1 to 4 Weeks) of Human Exposure. At first evalua-
tion, the Task Force divided this time period of human exposure
into 2 to 7 days and 1 to 4 weeks. A 7-day study was thought
to be the appropriate study for the 2- to 7-days exposure, and a
28-day study to be appropriate for 1 to 4 weeks. Ultimately, in
an effort to minimize animal use, the Task Force recommended
the use of one study, based on a common view that the difference
in toxicity would not be significant. (A preliminary suggestion
was a 14-day study; however, reservations existed. The 14-day
study duration does not allow observation of some delayed ef-
fects, such as some types of delayed, or peripheral, neuropathy.)
A 28-day study was therefore selected to cover the period from
2 to 28 days of human exposure. The study includes histology,
clinical chemistry, hematology, and other specialized investiga-
tions that may be indicated by structure activity or information
from other studies. It would include groups of animals treated for
28 days and then removed from treatment for a further 14 days
before being terminated, in addition to those animals terminated
immediately after 28 days of treatment. This protocol would
allow for the progression or regression of effects to be assessed.
Animal Study to Provide Data Relevant to 1 to 6 Months
of Human Exposure. A 90-day study was selected as being
the appropriate study for 1 to 6 months of human exposure.
The study includes histology, clinical chemistry, hematology,
and other specialized investigations that may be indicated by
structure activity or information from other studies.
Animal Study to Provide Data Relevant to Greater Than 6
Months of Human Exposure. A 12-month study was selected
to be the appropriate study for longer than 6 months of expo-
sure in humans. The study includes histology, clinical chemistry,
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hematology, and other special investigations that may be indi-
cated by structure activity or information from other studies.
There is no recovery group because the study duration is in-
tended to cover effects for an extended period of time and will
not contribute to an understanding of intermittent exposure.
At this stage of proposal development, the full study package
consisted of eight studies: four in the rat and four in the dog. The
Task Force proposed that the first study to be performed should
be the 28-day rat study, which would provide background data
in a reasonable period of time that is relevant for 2 to 28 days of
human exposure. The Task Force then considered whether all of
these studies would be necessary in all cases. It considered two
factors: the role of the second species and the influence of poten-
tial human exposure at each of the human exposure durations.
Refinement of the Proposal: Role of the Second Species
The dog is the second species that is used most frequently
in agricultural chemical safety assessment. It is a regulatory
requirement, except in special circumstances in which it can be
demonstrated that the dog is not relevant to humans. The second
species covers the possibility that the rat may be insensitive to
an effect of a compound to which humans are more sensitive.
The use of a second species that is phylogenetically removed
from the rat increases the likelihood that one or the other of the
species will be at least as sensitive as humans.
The SABRE database allowed the Task Force to determine
how often the dog was more sensitive than the rat (i.e., the
NOAELs and LOAELs derived in the dog were lower than in
the rat) and/or of different susceptibility (i.e., different effects
were observed). The conservative and health protective assump-
tion is that the dog is the more relevant model in these cases for
extrapolation to humans, and the derivation of RfDs is, there-
fore, from the dog data. In cases in which the dog is of different
susceptibility, the effects should be considered when selecting
the uncertainty or safety factor to be applied.
Figures 2 and 3 show the results of the interrogation of the
SABRE database comparing the NOAELs and LOAELs derived
from rat and dog studies with the same compounds. In each fig-
ure, a ratio of less than 1 indicates that the rat was more sensitive,
and a ratio of more than 1 indicates that the dog was more sen-
sitive. Inspection of the figures reveals that at 90 days there is
FIG. 2. Comparison of NOAELs and LOAELs in 90-day rat and
90-day dog studies.
FIG. 3. Comparison of NOAELs and LOAELs in 24-month rat
and 12-month dog studies.
an approximately normal distribution of sensitivity around unity
(5/19, i.e., 26% cases have ratios between 0.6 and 2), with an
equal number of situations (7/19, i.e., 37% cases) in which the
dog is more sensitive than the rat (ratios above 2), and the rat is
more sensitive than the dog (ratios below 0.6). Therefore, the dog
would be the species from which the RfD for 1 to 6 months of
exposure would be derived approximately one-third of the time.
The distribution for the longer term comparison is of a different
shape, but there is still a significant number of compounds for
which the dog is more sensitive. On the basis of this evidence,
the Task Force concluded that the dog could not be excluded as
a second species.
Once the need for the dog as a second species had been es-
tablished, thought was then given to how best to use the dog in
the new approach to safety assessment. Advantages to using the
dog include its utility as a better model for cardiovascular effects
and the ability to make assessments several times in the same
animals during the course of a study. It is also possible to take
serial blood samples from dogs to better understand toxicoki-
netics. The purpose of evaluation in the dog can be summarized
as follows:
• To determine whether there are significant new effects
in the dog when compared to the rat.
• To determine whether the dog displays the same effects
but is more sensitive.
• To assess effects on the cardiovascular system and pos-
sibly other systems as necessary.
• To assess toxicokinetics, including the option of assess-
ing kinetics after dermal exposure during preliminary
studies leading to a main study.
The Task Force agreed that performing a 90-day study in the
dog meets the objective concerning the relative sensitivity of the
rat and the dog, while at the same time providing information
that would be relevant for the 1 to 6 months human exposure
period. The study outline would include:
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• 90-Day capsule or dietary dosing.
• Toxicokinetics—six time points on day 1, week 4, and
week 13.
• Blood pressure and ECG—prestudy, day 1, week 4,
and week 13.
• Clinical chemistry and hematology—prestudy, day 1,
week 4, and week 13.
• Pathology.
The 90-day dog study should be a core study and the second
study carried out after the 28-day rat study.
If concordance exists between the 28-day rat and the 90-day
dog studies in terms of effects seen and the dose levels at which
the effects occurred, then either species could be used to further
define the toxicity of the compound. In this case, the default is
to use the rat for further studies. In reaching this conclusion,
it is advisable to consider the “internal dose” for each species
derived from toxicokinetics, rather than the “external” or applied
dose. In addition, it should be borne in mind that the dog study
is of a longer duration. It would be expected that the NOAEL in
the longer study could be lower, especially for compounds with
a long half-life or for compounds causing effects that are the
result of cumulative insult or injury. These factors are important
in determining whether the dog is the more sensitive species.
If the rat displayed effects at lower doses than the dog, then
the rat should be used in further evaluation of the compound.
If the dog showed different effects at lower doses or the same
effects at lower doses, then the dog should be considered for
further evaluation.
Assessing the Effects of Short-Term Human Exposure
The assessment of a single-day human exposure should be
done after the results of the 28-day rat study and the 90-day dog
study are available. These studies should indicate whether the
dog or the rat should be used for the assessment as described
earlier, taking into account the relevance of the endpoints for
acute exposure. It is also appropriate to consider the projected
human exposure at this stage. One would expect that toxicity
in terms of effects and dose levels observed after 1-day expo-
sure would be less than after 28- or 90-day exposure at the same
dose level. If the RfD derived from the 28-day rat and 90-day dog
study indicates an adequate margin of exposure, then the require-
ment to perform a single-dose study could be waived. However,
the decision to perform a single-dose study often needs to be
made early in the development of an agricultural chemical—
that is, before the chemical’s use rate and all of its potential
outlets have been determined. This may limit the opportunity
to waive the single-dose study on exposure grounds. However,
if the key effects observed in the dog can be assessed by the
parameters that will be measured on day one of the study (ECG,
blood pressure, clinical chemistry, clinical observations), then
the requirement to perform a single-dose study may be waived.
In addition, the single-dose study will be valuable in provid-
ing insight on the kinetics (speed of onset, recovery period) of
the effect caused by the compound. This information can be
used to assess intermittent and variable exposure as described
later (see The Proposed Tiered Testing Approach, Step 7). For
these reasons, it is expected that a single-dose study will be
performed more often than not. If such a study is done, then
it should conform to the design just outlined. It should never
be necessary to perform both the rat and the dog single-dose
study.
Assessing the Effects of Longer Term Human Exposure
The first step in assessing longer term (i.e., over 6 months)
human exposure is to determine whether the use pattern of the
compound will give rise to exposure longer than 6 months. Such
a scenario is likely to be the case for compounds that are used
throughout the year in tropical conditions, or for compounds
with residues in food or drinking water. If longer term expo-
sure is not predicted, then the requirement for longer term stud-
ies may be waived. Exposures to most agricultural chemicals
will be longer term; however, there may be exceptions, such as
rodenticides.
The Task Force determined the appropriate study duration
for chronic exposure to be 12 months, which represents an ap-
preciable fraction of the life span of the rat. Initially, the Task
Force was of the view that the results of the 28-day rat and 90-
day dog studies should be taken into account in deciding which
species to use for 12-month chronic toxicity studies. If the rat
was considered to be the more sensitive species, then the rat
should be used and, conversely, if the dog were the more sen-
sitive species, then the dog should be used. However, there is a
growing body of evidence to show that extending the duration
of exposure in dogs from 3 months to 12 months provides no
useful additional data (Spielmann and Gerbracht, 2001). In ad-
dition, 12 months is only a small fraction of the life span of the
dog. Interrogation of the SABRE database supports these con-
clusions. There were very few (two) cases in which differences
in sensitivity could not be attributed to the choice of lower dose
levels in the 12-month study. Dose levels in 12-month studies are
generally set slightly lower than in the preceding 90-day studies
on the assumption that effects will progress during the longer
duration; however, this assumption is not borne out in practice.
Nor were there any differences in the nature of the effects ob-
served. The Task Force recommends the use of the 12-month rat
study, carried out as an interim sacrifice in a 24-month carcino-
genicity study (see later discussion). Twelve months was chosen
rather than 24 months for this assessment because by 2 years,
age-related changes make interpretation of the data difficult,
and any noncancer effects should be evident after 12 months.
However, animals will be monitored for up to 2 years for any
noncancer effects that emerge after 1 year. The RfD based on
systemic toxicity for exposures of greater than 6 months should
be set using the lower of the NOAELs from the 12-month rat
chronic/24-month rat bioassay or the 90-day dog study.
The Task Force had concerns about the number of dogs
used in 90-day studies. The current minimum recommended
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by the Organisation for Economic Cooperation and Develop-
ment (OECD) in its Test Guideline Number 409 (OECD, 1998)
is four per sex per group, which can cause problems of inter-
pretation and loss of sensitivity if even one dog is withdrawn
from the study due to ill health or if one dog shows outlying
values. Taking into account statistical power, logistical issues in
animal husbandry, and humane considerations, the Task Force
recommends increasing the group size to six per sex per group
in the 90-day study.
The Relevance of Experimental Animal Study Duration
to Human Exposure Duration
There are a number of factors that need to be taken into
account when considering the relevance of the duration of an
experimental animal study to the duration of human exposure to
the same chemical. The simplest approach is to directly extrapo-
late the exposure duration in animals to humans; that is, a 1-day
exposure in an animal would be equivalent to 1 day in a human,
28 days in animals would be equivalent to 28 days in humans,
and so on. This appears to be satisfactory until the timescale
is extended, especially if the question is asked a different way;
that is, “What is the correct animal exposure duration to model
several years of exposure in humans?” The situation then be-
comes complicated by factors such as aging and percentage of
life span.
If there were no difference between durations of exposure in
animals and humans, then it would not be necessary to con-
sider performing studies of different durations. Clearly, this
is not the case. In order to seek better insight into this issue,
the factors that might change the nature of the response when
a chemical is given for different lengths of time need to be
examined.
Three major factors should be taken into account:
• The toxicokinetics of the chemical.
• The toxicodynamics of the response elicited by the
chemical.
• The influence of the proportion of the life span of the
subject on these factors.
The interaction of toxicokinetics (what the organism does to
the chemical) and toxicodynamics (what the chemical does to
the organism) has been discussed by Rozman and Doull (2000)
in terms of the time element of toxicity. They define toxicity as
“the accumulation of injury over short or long periods of time,
which renders the organism incapable of functioning within the
limits of adaptation.” The authors suggest that Paracelsus’ fa-
mous quote should be supplemented to read “Dose and time
together make the poison.” Rozman and Doull identified the
factors that underlie toxicokinetics and toxicodynamics:
Toxicokinetics:
• Absorption.
• Elimination.
Distribution.
Biotransformation,
Excretion.
Toxicodynamics:
• Injury.
• Recovery.
Adaptation.
Repair.
Reversibility.
Rozman and Doull point out that although the basic rela-
tionship is concentration × time = k, with this number of
variables available for interaction, the responses will be var-
ied and complicated to model. However, the extremes of vari-
ability can be predicted; that is, no elimination will lead to
linear accumulation of compound; no recovery will lead to
linear accumulation of injury. Each chemical will have its
own unique characteristics, depending on how the variables
interact. If all of the variables were known, it would be pos-
sible to predict the toxicity of a compound without further
experimentation.
Both toxicokinetics and toxicodynamics have their own in-
ternal time dependencies that dictate how dose and time will in-
teract. These time dependencies can vary from minutes to years
depending on the factors involved, but once they are understood,
they allow predictions to be made with confidence about the ef-
fect of any exposure duration.
The essence of the ACSA Systemic Toxicity approach is
an attempt to provide the optimum data base from which
the effect of dosing chemicals for different durations of time
can be predicted. The time dependencies of the toxicokinet-
ics will be defined as described by the ACSA ADME Task
Force (Barton et al., 2006). The studies of different durations
with recovery define the range of toxic effects and the time
needed to cause them or for them to be manifest. It will there-
fore be possible to deduce the time dependencies of the tox-
icodynamics from knowledge of the overall toxicity and the
toxicokinetics.
The question then remains; “How should the time depen-
dencies observed in experimental animals be extrapolated to
humans?” There are essentially two ways:
• Unadjusted duration.
• Percentage of life span.
The answer will depend on the effect being considered, but a
rule of thumb can be used that states that the shorter the time
dependency of an effect, the more likely it is that unadjusted
duration should be used, and the longer the time dependency,
the more the percentage of life span comes into play. Carcino-
genicity is the effect that is most often considered using a per-
centage of lifetime approach. It could, however, be argued that
the most appropriate factor is not the percentage of life span,
but the influence of life stage. The toxicodynamics of cancer
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FIG. 4. Comparison of ratios for 90-day studies in rats and dogs to longer term studies in the same species.
could be oversimplified to be described as an initial injury that
leads to cancer later in life when the repair mechanism, which is
stopping progression, breaks down. The most potent carcinogens
can cause early tumors or can cause tumors later in life follow-
ing a brief exposure early in life because of the magnitude of the
injury (and the mechanism/mode of action). In the experimental
models for carcinogenicity, an important factor seems to be to
impair the repair mechanism either by keeping the animals in the
standard rodent bioassay until they reach an age when this occurs
“normally” through senescence or by genetically modifying the
animals as in the shorter term mouse models.
Other effects that take a long time to occur, such as the
induction of lung fibrosis, which could be characterized as a
misdirected repair attempt, seem to take the same amount of
time to observe whether it is in the dog or the rat, independent
of the percentage of the life span of the animal.
If percentage of life span is the dominant factor, then it would
be expected that there would overall be a greater decrease in
NOELs in rats when comparing 90-day studies (10% of a 30-
month life span) to 24-month studies (80% of life span) than in
dogs, where a 90-day study represents 1.66% of a 15-year life
span and a 12-month study represents 7%. The limited data set
provided by SABRE does not bear this out; there is no differ-
ence in the distribution of the ratios of 90-day study to longer
term study NOELs between rats and dogs (Figure 4). There
could be two reasons for this: that direct extrapolation is the
assumption to be made, or that the time dependencies of the
toxicodynamics of most effects are such that a steady state is
reached after 12 months. There will be some exceptions, such
as have been discussed for carcinogenicity, when the life stage
changes one of the factors underlying the effect, such as repair
capacity.
The range of studies included in the ACSA project has been
designed to cover a range of exposure durations. It also cov-
ers studies of sufficient length to allow for the development
of effects with toxicodynamics with long time dependencies.
The inclusion of the 24-month rat study also allows for the
effect of age on kinetic and dynamic factors to be taken into
account.
Rationale for Dose Selection
Dose selection has a profound effect on the results of toxi-
cology studies. A major concern has been the setting of the top
dose for a study. The interpretation of studies designed to assess
specific toxic effects, such as carcinogenicity or endocrine mod-
ulation, is difficult when the specific effect only occurs in the
presence of marked systemic or general toxicity. There are two
approaches to setting the top dose for such studies: the maximum
tolerated dose and the limit dose.
Maximum Tolerated Dose
History and Definition. By the 1950s, it was generally ac-
cepted that small rodents were suitable surrogates for studying
the potential effects of chemical exposure in humans. It was not
until the 1960s that the concept of the maximum tolerated dose
(MTD) became established in the dose selection process for car-
cinogenesis studies (McConnell, 1995). The major architects of
the design and choice of the high dose—or what is now known
as the MTD—were Drs. John and Elizabeth Weisberger and
Umberto Saffiotti of the National Cancer Institute (NCI). While
testing several known human carcinogens, these scientists
found that it was necessary to use high dose levels to produce
cancer in rodents (McConnell, 1989). They defined the MTD as
“the highest dose of the test agent during the chronic study that
can be predicted not to alter the animals’ longevity from effects
other than carcinogenicity” (Sontag et al., 1976). They further
stated that the choice of the MTD should be based on the results
of a 90-day study where the highest dose caused “no more than a
10% weight decrement, as compared to the appropriate control
group; and does not produce mortality, clinical signs of toxicity,
or pathologic lesions (other than those that may be related
to a neoplastic response) that would shorten the animal’s life
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span.” In 1978, the NCI Carcinogenesis Bioassay Program was
transferred to the National Toxicology Program (NTP), where
the concept of the MTD further evolved. In 1984, the NTP
convened an ad hoc group of scientists experienced in the field
of carcinogenesis and toxicology. They were concerned that the
Sontag et al. (1976) definition was inadequate, and suggested
that it be supplemented with the following: “The MTD should
not cause morphologic evidence of toxicity of a severity that
would interfere with the interpretation of the study” (NTP,
1984). Unfortunately, while there has been a great deal of knowl-
edge gained since 1984 with regard to how chemicals interact
with the body, the definition of the MTD has not since been
updated.
Basis for Using the MTD in Carcinogenesis Bioassays. The
primary reason, objective, and/or justification for using the MTD
in carcinogenesis bioassays is to maximize the likelihood of de-
tecting a rodent carcinogen (National Research Council, 1993).
Using the MTD adjusts for the insensitivity of the animal model
being used, both biologically and numerically. The typical car-
cinogenesis bioassay uses only 50 animals per dose group as a
surrogate for thousands or even millions of people—the logic
being to maximize the dose (within reasonable limits) to the ex-
tent possible to make up for the small number of animals. Also,
the MTD can help in identifying potentially “weak” carcino-
gens, particularly those that cause an increased incidence of a
neoplasm that has a relatively high background incidence. An
additional advantage of using the MTD as the highest dose in
a carcinogenesis bioassay is to provide some degree of consis-
tency of design so that one can compare the results of one study
to another; that is, the MTD serves as a “benchmark.” For ex-
ample, if the dose (the MTD) showing carcinogenic activity for
chemical A is in the range of grams per kilogram compared to a
low milligrams per kilogram or even micrograms per kilogram
dose for chemical B, one would assume that chemical B was the
more “potent” and probably a greater hazard than chemical A,
unless there is a clear explanation for the dose difference, such
as lack of absorption.
A final advantage of using the MTD as the high dose in car-
cinogenicity studies is because it is consistent with dosing regi-
mens firmly entrenched in toxicology. For example, when one is
interested in the potential reproductive toxicity of a chemical of
unknown hazard, one normally uses a dose just below that con-
sidered maternally toxic. The same is true when one is interested
in the teratologic, immunologic, neurologic, etc. potential of a
chemical. Even in vitro studies used to study the genotoxicity of
a chemical normally use doses just below the lethal dose, which
arguably is equivalent to an MTD. Therefore, the use of an MTD
in carcinogenesis bioassays is consistent with the basic tenets of
toxicology.
However, the MTD also has some inherent disadvantages. For
example, the term “maximum” automatically connotes that an
“excess” amount of the chemical is used to produce a given ef-
fect. In this way, the MTD can be misleading to individuals who
do not have hands-on experience in the study of chemicals. This
is particularly true in the eyes of the general public who receive
their information through the general media (newspapers and
television), which rarely places the MTD in the context of hu-
man exposure. One approach to this misconception is to substi-
tute another term for the MTD, such as “minimally toxic dose,”
but use the same definition (Huff et al., 1994). This approach,
however, tends to obfuscate the problem rather than solve it.
Another disadvantage is the problem of inconsistent definition.
For example, two different groups of investigators viewing the
same data can differ in their views regarding whether the MTD
was attained.
A further important disadvantage is that it is difficult to inter-
pret the relevance to humans for effects that are found at doses
that exceed the MTD. For example, if carcinogenic activity is
only observed at doses that clearly exceed the MTD, should that
particular chemical be considered an animal carcinogen? Some
investigators would say “yes,” and others would say “yes, but
only at a dose which exceeds the MTD,” while others would
opt for placing the chemical in a noncarcinogenic category. This
is a particular problem for regulators and agencies that have to
classify chemicals/materials and place them on “lists.” When the
compounds in question are carcinogenic by a genotoxic mode
of action, there is at least some logic to such thinking. However,
when the compounds are not genotoxic, as is now the case with
those agricultural chemicals that progress to development, there
is no logic in classifying chemicals simply on a carcinogenic
response at very high doses.
A final disadvantage is that it may be practically impossible
to attain an MTD for chemicals with low toxicity. To compensate
for this scenario, practical limits (referred to as the “upper limit”)
have been accepted for studies using some routes of exposure, for
example, 1% of the diet, extent of solubility in water, or limit of
acceptance (palatability). There have also been upper exposure
bounds for inhalation studies that, for example, take into account
a chemical’s explosive potential or a practical maximum for a
dust.
Basically, dose influences mechanism and, over a wide range
of doses, mechanism can change with changing dose (Counts
and Goodman, 1995). Thus, a carcinogenic effect observed at a
high dose is not necessarily expected to occur at lower doses, es-
pecially when dealing with nongenotoxic chemicals (McClain,
1994).
Proposed Definition of the MTD. The concept of using the
MTD as the “highest” dose is still valid, but the definition needs
to reflect state-of-the-art science. Effects on body weight, mor-
bidity, mortality, or pathology, when present, will continue to be
valid endpoints when evaluating the results of short-term studies
for selecting the MTD for longer term studies. However, a more
science-based rationale is required.
In a practical sense, the chief concern with the MTD is
how the resulting data are used in the risk assessment process
(McConnell, 1989). The goal for risk assessment is to extrap-
olate rodent carcinogenicity data to estimate possible human
risks that might occur at much lower levels and frequency of
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exposure. A major problem arises when the accomplishment of
this goal is linked automatically to a procedure involving a lin-
ear dose-response, no-threshold assumption. Therefore, both the
criteria for selection of the high dose used and the no-threshold
default criterion must be reevaluated in a critical manner (NTP,
1992). In essence, the primary concern is that testing at the
MTD can result in toxicity, perhaps secondary to overload of
metabolic pathways, which can result in a carcinogenic effect
that would not occur at lower doses. A variety of examples,
including genotoxic as well as nongenotoxic compounds, illus-
trates this concept (reviewed in Counts and Goodman, 1995).
Gaylor (2005) analyzed the results of over 500 NTP bioas-
says. This analysis suggested that almost all of the chemicals
selected would produce a statistically significant increase in tu-
mor incidence at the MTD with larger sample sizes. Gaylor
concluded that the MTD bioassay screen is not distinguishing
between true carcinogens and noncarcinogens. Rather, the cur-
rent bioassay is possibly serving as a screen for the more po-
tent cytotoxins at the MTD, and not as a screen specifically for
carcinogenicity.
The definition of the MTD should also incorporate the find-
ings of properly conducted absorption, distribution, metabolism,
and excretion (ADME) studies. For example, if a chemical is
poorly absorbed, then an upper limit approach to selecting the
MTD would be used. Or if, at a given dose, metabolic sat-
uration is achieved, then that dose would be defined as the
MTD.
These concepts are in close agreement with guidance in the
U.S. EPA Draft Guidelines for Carcinogen Risk Assessment
(U.S. EPA, 2003a): “Other signs of treatment-related toxicity
associated with an excessive high dose may include (a) signif-
icant reduction in body weight gain (e.g., greater than 10%),
(b) significant increases in abnormal behavioral and clini-
cal signs, (c) significant changes in hematology or clini-
cal chemistry, (d) saturation of absorption and detoxification
mechanisms, or (e) marked changes in organ weight, mor-
phology, and histopathology.” The Health Effects Division
of the U.S. EPA Office of Pesticide Programs also provides
greater detail in an interim guidance document (U.S. EPA,
2003b).
The Derivation of Limit Doses
A limit dose of 1000 mg/kg/day is used for most repeat-
dose studies. The origin of this value is not apparent, but it
was probably chosen as a reasonably high dose, and it is lower
than single-dose limits of 2 g/kg or 5 g/kg. However, the re-
duction of the recommended limit dose as study duration in-
creases stops at 28 days. In practice, the limit dose of 1000
mg/kg/day results in a very high metabolic load on laboratory
animals, and it can lead to liver enlargement and kidney toxi-
city with otherwise relatively nontoxic chemicals. In turn, this
can lead to problems in assessing the results of specific toxicity
studies.
The Task Force considered whether it would be possible to set
limit doses based on an assessment of the maximum theoretical
human exposure level, followed by application of a margin of
exposure of 1000 from this level to determine the limit dose for
the study durations recommended in this proposal. However, no
firm conclusions could be drawn.
Assessing Toxicity That May Not Be Covered
in the Basic Studies
The major aim of the suite of basic studies outlined in Figure 5
is to answer the general question, “What is the range of target
organs affected and types of toxicity caused by the compound?”
A general screen of clinical conditions and observations, clini-
cal chemistry, hematology, and histopathology of major organs
is used to explore this question. However, it should be noted
that there are several manifestations of toxicity that may not be
covered by these basic studies:
• Local toxicity of the concentrated compound.
• Neurotoxicity.
• Immunotoxicity.
• Endocrine modulation.
• Genetic toxicity.
• Carcinogenicity.
Whenever possible, these specific manifestations of toxicity
should be identified by indicators in the basic studies that give a
high level of confidence that there is or is not a concern. If there is
a concern identified by an indicator in a basic study, then second-
tier studies can be performed to further characterize the effect in
terms of mode of action. To the extent possible, this philosophy
has been incorporated into the basic designs proposed here. The
discussion that follows reviews how each of these special areas
of toxicity can be addressed.
FIG. 5. Diagrammatic representation of the ACSA systemic
toxicity tiered strategy.
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Local Toxicity of the Concentrated Compound
It is important to evaluate the potential effect of the concen-
trated compound on those who may handle it. If an assessment
of oral lethality is necessary for classification purposes, then one
of the methods developed by the OECD that assesses lethality
while minimizing the use of animals should be employed. The
assessment of dermal and ocular irritancy has also been the sub-
ject of much recent scrutiny by the OECD. As new methods are
introduced in these areas, they should be adopted. Sensitization
assays have also been the subject of considerable review. The
Local Lymph Node Assay is now the method of choice for ac-
tive ingredients. However, it should be noted that this method
may not be appropriate for assessing the sensitization potential
of agricultural chemical formulations because the formulation
may run off the mouse ear, giving an underestimate of potency,
or the dosing vehicle may break down the formulation and over-
estimate the sensitizing potential.
The Task Force recommends that OECD methods be used to
assess the acute and local toxicity of the concentrated compound.
Neurotoxicity
The proposed standard 28-day rat and 90-day dog toxicity
studies (28/90-day studies) will evaluate functional, behavioral,
and morphological endpoints for the nervous system, which may
give preliminary or even definitive indications of the neuro-
toxicity of test materials. Moreover, if the test substance has
a neurotoxic mechanism of action, biochemical tests may be
performed on the nervous system to assess changes. For ex-
ample, if the test substance is a cholinesterase inhibitor, neu-
rotoxicity may be assessed in the 28/90-day study by perform-
ing cholinesterase measurements in nervous system tissue. Data
on the metabolism and pharmacokinetics of the compound will
be developed in support of the 28/90-day toxicity study, and
will aid in study design, dose selection, and interpretation of
the outcome. It is perhaps worth noting that while the half-
life of disposition of the compound may be short, the half-
life for recovery may be longer. Consequently, it is not pos-
sible to assume on the basis of ADME studies that, for exam-
ple, a 28-day study is not appropriate. Such information will
be invaluable in interpreting the result of studies of different
duration.
The 28-day rat toxicity study protocol includes both clin-
ical observations (i.e., cage-side monitoring of animals, as
well as during handling at the time of dosing or body weight
determination), a functional observational battery, and motor
activity assessment (Moser and MacPhail, 1990). These be-
havioral assessments should indicate changes in motor func-
tion (e.g., disturbances of gait, abnormal posture, or muscle
tone), level of arousal (e.g., hyperactivity, lethargy), autonomic
functions (salivation, lacrimation, urination, defecation), psy-
chological status (indicated by stereotypy, aggression, biting,
licking, self-mutilation), or pharmacological effects (sedation,
anesthesia).
In addition to the extensive functional assessment already
described, the 28-day rat study will also include a satellite
group of animals for morphological evaluation of the cen-
tral and peripheral nervous systems following fixation by
perfusion.
The neurotoxic assessments included in the 28-day rat and the
90-day dog studies should be sufficient to detect any potential
effects on the nervous system. If one or more of the predictive
markers is altered by treatment, then more specific tests may
be conducted to characterize the toxicity and/or assess potency.
These second-tier tests may include, but are not limited to, tests
of learning and memory, neurophysiology, or biochemical as-
sessment.
Immunotoxicity
Assessment of potential adverse effects on the immune sys-
tem is an important component of the overall toxicity evaluation
of chemicals. When appropriate endpoints are included in the
study design, evidence of immunotoxicity can be observed in
standard toxicology studies such as the proposed core 28-day
rat and 90-day dog studies.
Indications of immunosuppression, if expressed, will be eval-
uated in the proposed core studies as follows:
• Evidence of myelosuppression.
• Alterations in immune system organ weights and his-
tology (e.g., hypocellularity of immune system tissues
such as the thymus, spleen, lymph nodes, or bone mar-
row).
• Decreased serum globulin levels.
• Changes in hematology.
Thus, the following standard clinical and anatomic pathology
markers will be included in the 28-day rat study and 90-day dog
study specifications: serum biochemical markers such as globu-
lin levels, hematology (including differential), gross pathology
findings, immune system-related organ weights, and histologic
examination of immune system-related tissues (Basketter et al.,
1995).
Histology determinations will include examination of spleen,
thymus, lymph nodes, and bone marrow. In addition, the
lymphoid tissue that drains or contacts the site of chemical
administration (and therefore is likely to be exposed to the
highest concentration of the material) should be specifically
examined (Basketter et al., 1995). These sites include the gut-
associated lymphoid tissues (GALT) for orally administered
materials, bronchus-associated lymphoid tissues (BALT), and
nasal-associated lymphoid tissues (NALT) for materials ad-
ministered by the inhalation route, and the regional drain-
ing lymph nodes for chemicals administered by the dermal
route.
Typically, the outcome of the core studies, including assess-
ment of the endpoints just covered, is sufficient to detect any
potential effects on the immune system. If one or more of the
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predictive markers are altered by treatment and this cannot be
ascribed as secondary to general systemic toxicity, then consid-
eration should be given to conducting a subsequent functional
test (see later discussion). Such a functional test would explore
integrated function and further characterize dose response. As
with any other form of adverse finding in the core studies, the
lack of a NOAEL will require further characterization at lower
dose levels in a subsequent study.
Immune Function Studies. When warranted by observa-
tions in the core studies, additional studies to determine po-
tential for effects on immune function should be considered.
Other considerations are also important to determine whether
immune function studies should be conducted to explore the po-
tential adverse effects on immune function. Such considerations
include known class effects/SAR and observed pharmacokinetic
effects (e.g., high concentrations of chemical and/or metabolites
in immune system tissues).
When immune function studies are conducted, the most
widely accepted general method is experimental determination
of effect on immune response to a T-cell-dependent immunogen
(T-cell-dependent antibody response). The antisheep red blood
cell (SRBC) primary (IgM) antibody response assay (usually re-
ferred to as the “plaque assay”) was extensively evaluated by the
National Toxicology Program (NTP), and was found to be use-
ful in identifying immunosuppressant chemicals (Luster et al.,
1988, 1992a, 1992b, 1993). Modifications of the plaque assay
are available that can be used to determine effects on both IgM
and secondary (IgG) immune responses to SRBC (Holsapple,
1995). Other modifications of the plaque assay can be used to
determine effects on immune response to T-cell-independent
immunogen (Holsapple, 1995).
Endocrine Modulation
The potential for chemicals to interfere with endocrine pro-
cesses, especially those involved in reproduction and develop-
ment, is the subject of ongoing scientific and regulatory concern.
The most sensitive and informative signals of this potential can
be derived from studies performed to evaluate systemic toxicity
and reproductive and developmental effects. Endpoints capable
of detecting endocrine-related effects in these studies include
histopathological evaluation of gonads and sexual accessory or-
gans, thyroid, pituitary, and adrenals; male and female fertility;
reproductive timing and outcomes; and development of the off-
spring (e.g., measurement of anogenital distance, preputial sepa-
ration, vaginal patency, nipple/areolae retention, estrous cycling,
sperm evaluation, gross examination of reproductive organs and
other tissues, and histopathological evaluation).
The 28-day rat study, a core Tier 1 study as proposed in this
approach, is conducted on all compounds to provide a basis for
hazard characterization. As such, this study provides an early op-
portunity to evaluate the potential of substances to interact with
endocrine-related processes. Therefore, in addition to the stan-
dard organ/tissue weights and histopathology required by the
current test guidelines for this study (U.S. EPA, 2000; OECD,
1995), it is recommended that additional organ weights and
histopathology of tissues that are presently under consideration
in the “Enhanced” OECD 407 test guideline be included (OECD,
2000) (e.g., weight of testes, seminal vesicles and coagulating
glands, prostate, ovaries, thyroid, and uterus; and histopathol-
ogy of pituitary, vagina, epididymides, and mammary gland).
In addition, consideration may be given to the inclusion of es-
trous cyclicity and spermatology (number and morphology) and
the retention of serum samples for possible hormonal analy-
ses (e.g., T3, T4, TSH) pending study findings. Not only does
the evaluation of these endpoints in the 28-day toxicity study
provide an initial assessment of the potential of a chemical to
interfere with various endocrinological processes, but the infor-
mation obtained in this regard may have particular bearing on
the subsequent design of further studies to evaluate systemic
toxicity or reproduction and development.
The Tier 1 extended one-generation reproduction study in
rats proposed by the ACSA Life Stages Task Force (Cooper
et al., 2006) also includes a comprehensive evaluation of hor-
monally mediated endpoints as they pertain to reproduction,
growth, and development. The endpoints included are consis-
tent with recent revisions of the U.S. EPA OPPTS 870.3800 test
guidelines (U.S. EPA, 1998c) and OECD 416 test guidelines
(OECD, 2001), and those that have been more recently pro-
posed for the assessment of endocrine-modulating compounds.
The study design also includes the retention of three male and
three female F1 offspring per litter, all of which are moni-
tored for the onset of sexual maturity and undergo a gross
pathological examination at necropsy, thereby addressing con-
cerns regarding the potential sensitivity of the multigenerational
reproduction study to detect low-incidence reproductive-tract
malformations.
Changes in one or more parameters in Tier 1 studies would
usually lead to more focused investigations targeting poten-
tial endocrine mechanisms. Endocrine effects are usually at-
tributable to either direct effects at an endocrinological receptor
or effects on the activity of one or more enzymes involved in
the production and regulation of hormone levels. Assays such
as the Hershberger assay, the uterotrophic assay, and estro-
gen/androgen receptor-binding assays are useful for identifying
compounds with the potential to cause effects by action at the re-
ceptor level. Likewise, in vitro assays that assess steroid biosyn-
thesis and detailed hormonal analyses in whole animals are
useful in identifying substances with the potential to modulate
hormone production. These assays could be performed as sec-
ond tier studies if indications of hormonally mediated effects are
observed. Ultimately, mechanistic investigations should identify
the affected receptor or pathway involved, as such information
could be useful in refining the risk assessment and extrapolation
to humans.
Genetic Toxicity
The current genotoxicity testing strategies include four core
assays:
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• Bacterial mutation assay (Ames test).
• Mammalian cell mutation assay (L5178Y TK assay;
CHO HPRT).
• In vitro cytogenetic assay (usually metaphase analysis;
human peripheral lymphocytes; CHO; CHL).
• Bone-marrow cytogenetic assay (usually micronucleus
assay; rat; mouse).
The Task Force endorses a weight-of-evidence approach to the
evaluation of genotoxicity data, and recommends that further
developments in this specialized area be incorporated into the
safety assessment as they become generally accepted.
Carcinogenicity
The Task Force considered new experimental models for car-
cinogenicity involving the use of transgenic mice. A multilabo-
ratory research program coordinated by HESI was conducted
between 1996 and 2001 (Robinson and MacDonald, 2001).
Importantly, specific criteria for evaluation of the studies were
established at the outset in order to permit reliable comparisons
to be made of the results obtained from studies performed in mul-
tiple laboratories (Popp, 2001). This project was aimed at better
characterizing the responsiveness of several alternative mod-
els proposed for use in carcinogenicity assessments, including
the rasH2 and p53 +/− models. Alternative, genetically engi-
neered mouse models appear to have usefulness as hazard iden-
tification screening models. However, in isolation, these models
do not provide reliable evidence to assess potential human car-
cinogenicity (Cohen et al., 2001). They are not designed to be
employed as stand-alone assays; the results obtained from the
alternative models need to be evaluated in conjunction with other
basic toxicologic information (e.g., toxicokinetics, metabolism,
genotoxic potential, doses to which humans are likely to be ex-
posed, etc.) in an overall weight-of-evidence approach (Cohen,
2001; Goodman, 2001). Both the rasH2 and p53 +/− mod-
els were considered to be potentially useful when employed
as a component of an overall safety assessment (Cohen, 2001;
Goodman, 2001; Storer et al., 2001; Usui et al., 2001).
Pritchard et al. (2003) examined existing data on the use
of transgenic mouse models for identification of human car-
cinogens. The focus was on the most extensively used of these
mice—including the rasH2 and p53+/−models—and their per-
formance was compared with the standard 2-year bioassay. The
results obtained from the models were used alone and in combi-
nation. Data on 99 chemicals were evaluated, including results
from the HESI program (Robinson and MacDonald, 2001). The
authors made no interpretative conclusions concerning study
results, and, for assessments of possible human cancer risk, the
conclusions reached by the International Agency for Research
on Cancer (IARC) and the National Toxicology Program’s Re-
port on Carcinogens (ROC) were accepted. The combined strat-
egy using the p53 +/− model (for genotoxic compounds) plus
the rasH2 model (for both genotoxic and nongenotoxic com-
pounds) made the “correct” call (positive for carcinogens and
negative for noncarcinogens) for 88% of the chemicals. For
comparison, identical analysis of chemicals in this dataset that
were tested in the standard 2-year, two-species rodent bioassay
yielded “correct” calls for 69% of the chemicals. Although the
alternative models had a high percentage of correct calls, they
did miss five chemicals that IARC and/or ROC identify as known
or probable human carcinogens. The standard bioassay missed
none of these compounds; however, it did yield a substantial
number of false positives.
It is instructive to examine the five IARC and/or ROC com-
pounds that were reported as “missed” by the rasH2/p53 +/−
combination in the Pritchard et al. (2003) analysis:
• Cyclosporin A: A potent immunosuppressive. The
mechanism of carcinogenic action is very likely due
to its pharmacologic action. Though a nongenotoxic
compound, it is positive in the p53 +/− model; thus, it
was missed in the Pritchard et al. analysis because the
investigators limited the p53 +/− model to genotoxic
compounds.
• Estradiol 17β: Stimulates cell proliferation in sensitive
cell populations.
• Phenacetin: Human urothelial tumors arise from
chronic abuse, with a proliferative response to chronic
cytotoxicity and necrosis. One report by Yamamoto
et al. (1998) indicates that it is positive in the rasH2
model.
• Phenobarbital: Causes hypertrophy and hyperplasia in
rodent liver. Epidemiology data indicate no evidence
for carcinogenicity in humans.
• Chloroform: High doses cause chronic toxicity, necro-
sis, and compensatory hyperplasia in rodent liver and
kidney.
Even if the carcinogenic potential of these compounds had not
been detected in other studies, their toxicity would have been
detected, resulting in health-protective RfDs that also protect
against carcinogenicity.
In all evaluations of the carcinogenicity of agricultural chem-
icals, each compound is the subject of a genotoxicity evaluation.
It is assumed that only compounds viewed as having no signifi-
cant genotoxic potential will continue in development.
The Task Force supports the view that the conventional
mouse bioassay does not add significant additional informa-
tion for carcinogenicity evaluation over and above the use of
the 24-month carcinogenicity assay in the male and female rat
(Battershill and Fielder, 1998; Cohen, 2004; Monro, 1993; Usui
et al., 1996; Van Oosterhout et al., 1997). The Task Force agrees
that the 24-month rat carcinogenicity assay is adequate to detect
carcinogens, including those which only cause carcinogenicity
following prolonged perturbation of physiological mechanisms.
As such, it is the most appropriate assay for those compounds
with prolonged exposure, that is, over 6 months. In these cases,
the 24-month carcinogenicity assay should be combined with
the 12-month rat study described earlier. The evaluation of the
potential to cause cancer should involve the consideration of the
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TABLE 6
Final proposed ACSA systemic toxicity study grid
Human exposure Systemic
duration toxicity study Carcinogenicity
24 hours or less Single-dose rat
or dog
Genotoxicity battery
2 to 28 days 28-day rat or
90-day dog
Genotoxicity battery
1 to 6 months 90-day dog or
28-day rat
Genotoxicity battery
Over 6 months 12-month rat or Genotoxicity battery,
90-day dog 24-month rat
complete database, including evidence of chronic toxicity and
determination of modes of toxicity presumed to occur in humans,
not just the result of any single study. Ongoing work by HESI
and others on the identification and evaluation of the modes of
action of chemical carcinogens may lead to approaches for the
assessment of carcinogenicity by alternative means other than
lifetime studies in rodents. The Task Force recommends that,
if and when such approaches become available, they should be
adopted for the evaluation of agricultural chemicals as part of
the tiered approach proposed here.
When human exposure is of shorter duration, that is, 1 to 6
months, the situation is less clear. In practice, the number of
compounds for which this can be assured is small, given the
wide variety of uses of most compounds. A need exists for an
assay that will detect those compounds that are capable of caus-
ing carcinogenicity following a short exposure of 1 to 6 months,
even if the latency period before observing carcinogenicity is
lengthy. The most obvious mechanism by which this could oc-
cur is via genotoxicity, and there is no evidence that there is a
need to detect other mechanisms. The battery of in vitro and in
vivo models that is currently used should be adequate to detect
potential genotoxic carcinogens among the small group of com-
pounds with exposure durations of less than six months with
limited, non-domestic use. Any other mechanism will almost
certainly involve a response secondary to physiological pertur-
bation, e.g., DES, and this should be readily detected in the pro-
posed shorter-term studies. Additional toxicity data from studies
with longer exposure durations will also be available from the
life stages studies (Cooper et al., 2006). See Table 6 for the Task
Force’s proposed final systemic toxicity study grid.
Role of ADME in Assessing Systemic Toxicity
The most pragmatic route of exposure to be used in the core
studies is the oral route. This route is obviously of direct rele-
vance to dietary exposure. Although most operator exposure is
via the dermal route, with some contribution from inhalation,
there are confounding technical issues in performing dermal
studies. Dosimetry is difficult, with much of the applied dose
remaining on the occlusive dressing. Animal welfare issues also
exist. For example, bandaging animals for extended periods of
time can cause significant distress. To design and interpret such
studies for maximum utility for routes other than the oral route,
knowledge of the absorption, metabolism, distribution, excre-
tion, and kinetics (ADMEK) of the chemical is required. A ba-
sic exploration of the ADMEK of a chemical should be con-
ducted before the commencement of core studies. Assessment
of the toxicokinetics of agricultural chemicals is reviewed by
the ACSA ADME Task Force in Barton et al. (2006). The data
can then be used in dose selection and to estimate measures of
internal dose. Special care should be taken when extrapolating
between exposure durations for chemicals that accumulate or
have long half-lives.
Studies will be required to understand the absorption of the
chemical by other relevant routes such as dermal and inhalation,
and whether any route-specific metabolism is to be expected.
These data can then be used in conjunction with the results of
the core toxicity studies in which the toxicity is related to the
internal dose rather than the administered oral dose to provide
hazard characterization for risk assessment. These studies will
also demonstrate whether there are any significant effects on the
lung or skin caused by direct administration of the chemical.
Therefore, it should be the aim of the overall systemic toxic-
ity evaluation to determine an “internal dose” for each exposure
duration that can be used to set an RfD for risk assessment.
This dose can then be used to assess the potential effect of each
route of exposure by using the specific absorption and kinetic
data for each route. The “external” exposure dose will be deter-
mined by the various methods of estimating exposure that are
currently used or that will be developed in the future. They will
then be converted to the “internal” dose using route-specific in-
formation. In this way, multiple routes of exposure can also be
accommodated.
Incorporation of In Vitro Methodology and New
Technologies in Systemic Toxicity Assessment
The chemicals that will be assessed using the proposed tiered
approach devised by the Task Force will be the “survivors” of rig-
orous selection processes within agricultural chemical compa-
nies. In such a selection process, the first evaluation is for the ef-
ficacy in providing an effect useful to agriculture. Once efficacy
has been established, the potential to cause adverse health and
environmental effects is examined. At this stage, many compa-
nies employ sophisticated screening and evaluation batteries that
include consideration of structure activity and in vitro assays,
such as cell culture methods for cytotoxicity, embryo culture
methods for teratogenicity, in vitro metabolism, and receptor-
binding assays for neurological and endocrinological activity.
No company would embark on an expensive development pro-
gram for a new chemical unless it is confident that there would
be a high chance of success. It is difficult to know how these tests
which are currently used for selection purposes could be further
developed to give definitive information on safety without the
need for extensive in vivo studies. This, however, should be a
long-term goal of the regulatory scientific community.
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To promote this technical goal, there is increasing interest in
utilizing novel technologies derived from computational chem-
istry, molecular biology, and systems biology for toxicologi-
cal risk assessment. This new area is referred to as “computa-
tional toxicology.” In assessing risk associated with exposure to
a chemical, there are a number of uncertainties that lie along
a continuum, beginning with the presence of the chemical in
the environment, the uptake and distribution of the chemical
in the organism, the presence of the active chemical at a sys-
temic target site, and the series of biological events that lead to
the manifestation of an adverse outcome that can be used for
risk assessment. The goal of computational toxicology is to use
emerging technologies to improve quantitative risk assessment
and reduce uncertainties. The objective includes gathering data
on chemical transformation and metabolism, prognostic molec-
ular markers, improved dose metrics, characterization of toxic-
ity pathways, metabonomics, system biological approaches, and
modeling frameworks and uncertainty analysis. Computational
toxicological approaches may help design studies by predicting
potential adverse effects of concern and adding relevant end-
points into the Tier 1 studies.
The approaches that currently hold the greatest potential for
assisting in screening new active ingredients and identifying
what potential toxicity pathways may be of greatest concern for
a new compound are genomics, proteomics, and metabonomics.
Defining toxicity pathways associated with initiating events en-
ables one to associate endpoints through multiple levels of biol-
ogy and, ultimately, to an adverse outcome. Demonstration that
toxicity pathways are similar across species and within chemical
classes would reduce uncertainty associated with extrapolation
across species, and potentially decrease the number of studies
required to determine the spectrum of adverse health effects.
In the early phase of this developing technology, the greatest
benefit appears to be in helping to explain how adverse effects
may develop, identifying or confirming a suspected mode of ac-
tion, and, in species extrapolation, by showing concordance of
mechanisms between laboratory animals and humans.
New technological advances hold promise in the development
of high throughput screens. These rapid and efficient approaches
are a means to provide preliminary effect data on chemicals be-
ing considered for further testing. They also have the potential to
make significant advances over traditional toxicity testing by in-
creasing the rate of throughput, sensitivity, reproducibility, and
reduction in animal use. In brief, these new technologies would
include both in vivo and in vitro biological systems in which
the active ingredient is tested, RNA and/or protein isolated from
the cell culture or target tissues, and subsequent genomic or
proteomic assays utilized to identify markers of toxicity that sug-
gest the potential for particular adverse health effects to occur.
Role of Human Data in Risk Assessment
Human in vivo data, for the most part, will not be available to
aid in the design and interpretation of the animal studies that are
the focus of the Task Force’s proposed tiered testing approach.
When available, however, and derived from studies that meet
rigorous scientific and agreed-on ethical standards, human data
can provide valuable information to refine risk assessments, es-
pecially when there is a clear difference in metabolism and/or
kinetics between the animal test species that results in different
sensitivity or susceptibility to the compound. ADME studies in
humans at less than the LOAEL or even at the NOAEL can pro-
vide guidance on which experimental species may be the more
relevant to humans (NRC, 2004), and in some cases can pro-
vide the basis for the derivation of chemical-specific adjustment
factors (CSAFs) (IPCS, 2001). Similarly, human in vitro data,
particularly on kinetics and metabolism, may assist in study in-
terpretation and in the development of CSAFs. In some cases,
human data have been used to derive RfDs, which are lower than
the RfDs derived from animal data (Dourson et al., 2001).
The use of human data is currently an area of active debate.
Neither the United States nor the European Commission (EC)
has yet formulated policies concerning the use of human data,
although both are considering the issue carefully. For example,
the U.S. EPA recently issued “a plan to establish a compre-
hensive framework for making decisions about the extent to
which it will consider or rely on certain types of research with
human participants” (U.S. EPA, 2005). The Task Force recom-
mends that scientists, risk assessors, and decision-makers stay
informed about evolving policies and guidelines regarding the
use of human data in risk assessment.
Number of Animals Used in the Proposed Tiered
Approach Versus the Current Paradigm
The total number of animals used in the current core testing
paradigm for systemic toxicity has been estimated and is shown
in Table 7. Of course, additional animals are used for assessment
of acute lethality, skin and eye irritation, skin sensitization, and
short-term genotoxicity tests. The number of animals used for
these latter studies will not be any different in the proposed tiered
testing strategy compared with current practice. A total of 1272
experimental animals is needed for the current core studies.
The following examples illustrate likely animal use following
the introduction of the proposed tiered testing approach.
The study requirements and numbers of experimental ani-
mals needed are shown in Table 8. For the 28-day rat study,
the protocol assumes three treated groups with satellite and re-
covery groups at all dose levels in both the main study and the
satellite groups. For the 90-day dog study, the protocol assumes
three treated groups of six per sex per group. The 24-month rat
study includes an interim sacrifice at 12 months for assessment
of chronic toxicity.
A total of 768 experimental animals is needed for the pro-
posed tiered testing approach. The biggest savings in animal use
arises from the elimination of the mouse carcinogenicity bioas-
say. A comparison of the estimated numbers of animals used in
the current core studies versus those used in the core studies of
the proposed tiered testing approach are presented in Table 9.
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TABLE 7
Estimated total number of animals used in the current core
testing paradigm for systemic toxicity
Number of Number/
experimental sex/ Total
Study groups group required
Current studies in the rat
28 day 4 5 40
90 day 4 10 80
Acute neurotox 4 10 80
90-day neurotox 4 10 80
24 month 4 50 400
Total rats 680
Current studies in the mouse
28 day 4 5 40
90 day 4 10 80
18 month 4 50 400
Total mice 520
Current studies in the dog
28 day/6 week 4 1 8
90 day 4 4 32
12 month 4 4 32
Total dogs 72
Total number of animals used in current studies
Total (rats, mice, dogs) 1272
THE PROPOSED TIERED TESTING APPROACH
The Appendix describes the design and specifications of the
key systemic toxicity studies in the proposed ACSA tiered test-
ing approach. Successful operation of the approach will demand
the use of judgment at a number of key steps as described next.
Step 1: Consider Existing Knowledge
When embarking on the evaluation of a new agricultural
chemical, it is important to consider what information is al-
ready known. Such information will include structure–activity
relationships for members of a chemical series, the mode of ac-
TABLE 8
Estimated total number of animals used in the core studies of
the proposed ACSA tiered testing approach for systemic
toxicity
Number of
experimental Number/sex/ Total
Study type groups group required
Single-dose rat 4 5 80
28-day rat 4 20 160
90-day dog 4 6 48
24-month (including 4 60 480
12-month interim)
Total animals 768
TABLE 9
Estimated total number of each species of experimental
animals used in the core studies of the proposed ACSA tiered
testing approach for systemic toxicity
Animals Current paradigm New paradigm
Rats 680 720
Mice 520 0
Dogs 72 48
Total 1272 768
tion for members of a mechanistic series, and data that may have
been generated in the selection process. These data will suggest
to the investigator whether there are any special features that
should be included in the subsequent evaluation, such as particu-
lar modes of action that would require specific assessments (e.g.,
measurement of cholinesterase inhibition for organophosphates
or measurement of plasma tyrosine levels for HPPD inhibitors).
The first data to be generated in the formal evaluation are ADME
data in the rat. ADME data will help in the design of the core
studies by identifying compounds with specific properties (for
example, chemicals with particularly long half-lives such as an-
ticoagulants). In addition, all compounds will have assessments
of oral and dermal acute toxicity, dermal and ocular irritation,
sensitization, and genetic toxicity.
Step 2: Perform the 28-Day Rat Study
The 28-day rat study will be performed taking into account
information from Step 1. The doses are set using information
from preliminary studies, such as those that may have been con-
ducted during the selection process and toxicokinetics data that
will have been generated before determination of final doses.
The data for the indicators of neurotoxicity, endocrine modula-
tion, and immunotoxicity should be considered to determine if
second-tier studies are needed to further characterize any effects.
Step 3: Perform the 90-Day Dog Study
The 90-day dog study is performed taking into account in-
formation from Step 1. The doses are set on the basis of a pre-
liminary dog study, which should also include an assessment of
kinetics by both the oral and dermal routes.
Step 4: Consider the Relative Sensitivity
and Susceptibility of the Rat and Dog
The results of the 28-day rat and the 90-day dog studies should
be compared to determine relative susceptibility (i.e., what ef-
fects occurred) and relative sensitivity (i.e., at what dose levels
the effects occurred). The purpose is to identify the species that
will be used to provide guidance for human health protection.
In the absence of information to the contrary, the species cho-
sen will be the one that provides the lower RfD. Effects in this
species are used to determine the relevant uncertainty factor,
which is then applied to the NOAEL. Note that the rat study will
have been conducted for a shorter duration than the dog study.
60 J. E. DOE ET AL.
Therefore, it would be expected that the rat 28-day NOAEL
may be higher for compounds with cumulating kinetics or for
those causing effects that become more severe with repeated
insult or injury. As a rule of thumb, the rat 28-day NOAEL
could be divided by a factor of 3 before being compared with
the dog 90-day NOAEL. To the extent possible, the comparison
of dose levels should be based on knowledge gained from toxi-
cokinetics, which elucidates internal, rather than applied, dose.
The conservative assumption that the more sensitive species is
more relevant can also be confirmed or rebutted on the basis of
additional scientific knowledge.
Step 5: Derive the RfD for Human Exposure Durations
Up to 6 Months
Scenario 1: The Rat is the “Relevant” Species
Human exposure durations of 2 to 28 days should be consid-
ered by deriving an RfD from the 28-day rat study by dividing
the NOAEL by an appropriate uncertainty factor.
Human exposure durations of up to 1 day should be consid-
ered by deriving an RfD from an endpoint from the 28-day rat
study relevant for acute exposure by dividing the NOAEL by
an appropriate uncertainty factor. If the RfD derived from the
28-day rat study indicates an adequate margin of exposure, then
the requirement to perform a single-dose study could be waived.
However, the decision to perform a single-dose study often needs
to be taken early in the development of an agricultural chemi-
cal, that is, before the chemical’s use rate and all of its potential
outlets have been determined. This may limit the opportunity to
waive the single-dose study on exposure grounds. In addition,
the single-dose study is valuable in providing insight into kinet-
ics (speed of onset, recovery period) of the effect caused by the
compound. This information can be used to assess intermittent
and variable exposure as described in Step 6. For these reasons,
it is expected that a single-dose study will be performed more
often than not.
Human exposure durations of 1 to 6 months should be con-
sidered by deriving an RfD by dividing the NOAEL by an ap-
propriate uncertainty factor from the 90-day dog study if the
two species are considered to be of equal sensitivity. If the rat
is more sensitive, then the results of the 28-day rat study should
be used with an additional factor of 3.
Scenario 2: The Dog is the “Relevant” Species
Human exposure durations of 2 to 28 days should be consid-
ered by deriving an RfD from the 90-day dog study by dividing
the NOAEL by an appropriate uncertainty factor.
Human exposure durations of up to 1 day should be con-
sidered by deriving an RfD from an endpoint from the 90-day
dog study relevant for acute exposure by dividing the NOAEL
by an appropriate uncertainty factor, or by considering the re-
sults of the first day of dosing if the effect can be determined by
the recorded parameters. If the RfD derived from the 90-day dog
study indicates an adequate margin of exposure, then the require-
ment to perform a single-dose study could be waived. However,
the decision to perform a single-dose study often needs to be
made early in the development of an agricultural chemical, that
is, before the chemical’s use rate and all of its potential out-
lets have been determined. This may limit the opportunity to
waive the single-dose study on exposure grounds. In addition,
the single-dose study will be valuable in providing insight on the
kinetics (speed of onset, recovery period) of the effect caused
by the compound. This information can be used to assess inter-
mittent and variable exposure as described in Step 7. For these
reasons, it is expected that a single-dose study will be performed
more often than not.
Human exposure durations of 1 to 6 months should be con-
sidered by deriving an RfD by dividing the NOAEL by an ap-
propriate uncertainty factor from the 90-day dog study.
Step 6: Derive the RfD for Human Exposure Durations
Over 6 Months
Scenario 1: The Rat is the “Relevant” Species
If there is human exposure duration of greater than 6 months,
then a 24-month rat study with a 12-month interim sacrifice
should be performed to assess chronic toxicity and carcinogenic-
ity. An RfD for chronic toxicity should be derived by dividing
the 12-month interim sacrifice NOAEL by an appropriate un-
certainty factor. The results of the 24-month phase of the study
should be used to assess carcinogenicity. Subsequent classifica-
tion and risk assessment of the compound would then be done
following established national and regional policy. If a signif-
icant nonneoplastic effect emerges only in the second year of
the study, then it should be taken into account when deriving a
lifetime RfD.
Scenario 2: The Dog is the “Relevant” Species
If the duration of human exposure is likely to be greater than
6 months, then a 24-month rat study with a 12-month interim
sacrifice should be performed to assess chronic toxicity. An RfD
should be calculated both from the rat study and the 90-day dog
study. This should be done taking into account the nature of the
effects observed. In the absence of information to the contrary,
the lower RfD should be used for risk assessments for expo-
sure durations of over six months. The results of the 24-month
phase of the rat study should be used to assess carcinogenicity.
Subsequent classification and risk assessment of the compound
would then be done following established national and regional
policy.
Step 7: Derivation of RfDs for Varying
and/or Intermittent Exposures
Although many risk assessments assume a constant expo-
sure level throughout the duration of exposure, in most cases
the exposure levels do vary. The question arises as to how these
variations should be considered. Should a time-weighted aver-
age be used over the entire exposure period no matter what the
day-to-day variation may be, or should the RfD not be exceeded
for any given day? This question can only be addressed with cer-
tainty when the toxicokinetics of the compound and the kinetics
of the effect are taken into account.
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TABLE 10
NOAELs from 90-day rat, 24-month rat, 90-day dog, and 12-month dog studies compared with the lowest NOAEL excluding the
12-month dog study (SABRE data)
90-Day rat 90-Day dog 1-Year 2-Year rat Lowest Lowest NOAEL
Active Chemical NOAEL NOAEL dog NOAEL NOAEL NOAEL excluding
ingredient class (mg/kg/day) (mg/kg/day) (mg/kg/day) (mg/kg/day) all studies chronic dog
2,4-D Phenoxyacid 15 1 1 5 1 1
Acetochlor Acetanilide 80 10 2 10 2 10
Atrazine Triazine 1 6 5 3.5 1 1
Butylate Carbamate 32 45 5 100 5 32
Carbaryl Carbamate 125 1 3.1
(LOAEL)
10 1 1
Cyprodinil Anilinopyrimidine 3 46 — 2.7 2.7 2.7
Diazinon Organophosphorothioate 0.3
(LOAEL)
0.02
(LOAEL)
0.004 20 0.004 0.006
(LOAEL/3)
Glufosinate Phosphinic analogue of 3.2 2 5 2 2 2
ammonium glutamic acid (LOAEL)
Hexaconazole Triazole 3 5 2 4.7 2 3
Mevinphos Organophosphate 0.25
(LOAEL)
0.0625
(LOAEL)
0.025 0.025 0.025 0.025
Prallethrin Pyrethroid 24 3 5 16.3 3 3
Tebuconazole Triazole 9 73 2.9 5 2.9 5
Triallate thiocarbamate 3 2 1.275 NA
(0.5 = LOAEL)
0.5
(LOAEL)
0.5
(LOAEL)
Vinclozoline Dicarboximide 4 3 2.4 1 1 1
Dicamba Dichlorobenzoate 250 6 52 ≥125 6 6
Dimethoate Organophosphate 2 <0.25 <0.18 0.05 0.05 0.05
Chlorfenapyr Pyrrole 24 4 4 No study 4 4
MCPA Dithiocarbamate 7 3 1.75 4.38 1.75 3
Metolachlor Acetanilide 23 10 9.7 15 9.7 10
Benomyl Benzimidazole 25 13 12.5 >125 12.5 13
Propachlor Acetanilide 75 38 6.25 2.4 2.4 2.4
2,4-DB Phenoxyacid 16 8 <2.39 3 2.39 3
Fosetyl-AL Organophosphate 365 274 250 400 250 274
Iprodione Dicarboximide 78 60 17.5 6.1 6.1 6.1
Bifenthrin Pyrethroid 3 2 1.3 2.5 1.3 2
Carboxin Oxathin 6 8 No study 0.8 0.8 0.8
Dicofol organochlorine 0.64
(LOAEL)
2.5
(LOAEL)
0.12 1 0.12 0.2
(LOAEL/3)
Lactofen Diphenyl ether 14 75 0.79 0.79 0.8 0.8
For instance, consider a chemical that has a very long half-
life such that it accumulates in the body. Adverse effects are
observed when the body burden reaches a certain level. It is likely
that for such a chemical the RfDs derived from the proposed
tiered testing approach would be significantly lower with longer
duration of exposure. For such chemicals, it would be sensible
to apply the time-weighted average approach.
At the other extreme, consider a chemical that has a short
pharmacological, but no lasting, effect. If it also has a short
half-life, it is likely that the RfDs derived from the proposed
tiered testing approach will be similar no matter what the du-
ration of exposure. In these cases, the individual daily expo-
sure should be considered, rather than the cumulative or time-
weighted value.
The proposed ACSA tiered testing approach is designed to
give information to help characterize the compound. The toxi-
cokinetics package defines the half-life and provides information
on whether the chemical is likely to reach a higher level of inter-
nal dose as exposure progresses. The single-exposure study and
the recovery period in the 28-day rat study give insight into the
kinetics of the effects, whether there is recovery and, if so, over
what period. A major objective of the single-exposure study is,
in fact, to provide this information. Consequently, consideration
should be given to performing the single-exposure study.
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The proposed tiered testing approach provides the risk as-
sessor with RfDs for each of the human exposure time periods
(1 day, 2 to 28 days, 1 to 6 months, and greater than 6 months).
These RfDs can be used to provide guidance on how to assess
varying and intermittent exposures in the following way:
• The time-weighted average daily dose for any given
portion of the exposure should not exceed the relevant
RfD.
To expand this principle:
• No single day’s exposure should be above the 1-day
RfD.
• The time-weighted average daily exposure for any pe-
riod of 2 to 28 days should not exceed the 2- to 28-day
RfD.
• The time-weighted average daily exposure for any pe-
riod of 1 to 6 months should not exceed the 1- to 6-
months RfD.
• The time-weighted average daily exposure for any pe-
riod of 6 months should not exceed the over-6-months
RfD.
This guidance holds for compounds at both ends of the spectrum,
because, as explained earlier, the relationship between the RfDs
will reflect their properties.
EVALUATION OF THE PROPOSED TIERED
TESTING APPROACH
The proposed ACSA tiered testing approach differs in two
significant ways from the current testing scheme:
• It contains new elements designed to provide more rel-
evant data for deriving RfDs for shorter time periods
FIG. 6. Ratio of lowest NOAELs from 90-day rat, 24-month rat, 90-day dog, and 12-month dog studies compared with the lowest
NOAEL, excluding the 12-month dog study.
of human exposure, for example, a single-dose study,
a 28-day rat study with recovery period, and kinetics.
It is not possible to evaluate the impact of these new
studies by using the existing database.
• It contains fewer studies to derive the longer term RfD,
that is, neither a 12-month dog study nor a mouse
carcinogenicity study is recommended. The SABRE
database described earlier has been used to evaluate
the theoretical performance of this aspect of the pro-
posed tiered approach. The database contains a set of
28 chemicals for which the majority of relevant study
types that comprise the components of the current sys-
temic toxicity testing paradigm for agricultural chemi-
cals are represented. These core studies are the 90-day
studies in the rat and dog, the combined chronic and
carcinogenicity study in the rat, and the carcinogenicity
study in the mouse.
Impact of Removing the 12-Month Dog Study
Generally, the longer term RfD is derived by applying a safety
or uncertainty factor to the lowest NOAEL from the 90-day rat
study, the 24-month rat study, the 90-day dog study, and the
12-month dog study. The impact of removing the 12-month dog
study has been evaluated by comparing the lowest NOAEL from
these four studies with the lowest NOAEL derived from the three
studies that remain, if the 12-month dog study is not considered.
These studies are summarized in Figure 5 and the results of this
evaluation are shown in Table 10 and Figure 6. For only two
compounds in the database, acetochlor and butylate, would the
lowest NOAEL from the other three studies be more than twice
the NOAEL for the 12-month dog study. The data for acetochlor
are confounded by the presence of two 12-month dog studies—
one with a NOAEL of 2 mg/kg/day, giving a ratio of 5, and one
with a NOAEL of 12 mg/kg/day, giving a ratio of 1. Both values
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are shown in Figure 6. Butylate is more problematic. The 12-
month dog study has a much lower NOAEL, and the LOAEL
is above the NOAEL for the 90-day dog study; therefore, the
difference is unlikely to be caused by a dosing artifact. However,
the NOAEL for the 90-day rat study is lower than that for the 24-
month rat study. The entire database for butylate can be regarded
as unusual.
Impact of Removing the Mouse Carcinogenicity Study
The impact of removing the mouse carcinogenicity study
was discussed earlier. To review, tumors were detected in the
rat, with 13 of the 27 chemicals remaining in the analysis (six
of these also induced tumors in the mouse). An additional four
chemicals induced mouse tumors in the absence of findings in
the rat; however, all but one of these chemicals resulted in liver
tumors (see Tables 4 and 5). The relevance of the modes of action
for these mouse liver tumors for human health is questionable.
CONCLUSION
The proposed tiered testing approach for agricultural chemi-
cal safety assessment includes a number of key principles:
• The core 28-day rat study is the most comprehensive
initial assessment of toxic potential, and includes satel-
lite groups for the assessment of neuropathology at ev-
ery dose level, an assessment of recovery/progression
of general toxicity at all dose levels, and neuropathol-
ogy at all dose levels.
• The core 90-day dog study includes an assessment
of recovery/progression at all dose levels. The stan-
dard study design can be augmented to include satellite
groups for specific endpoints such as neuropathology if
indicated from the results of preceding studies in either
the rat or the dog (e.g., for range finding).
• The 24-month combined chronic toxicity/carcino-
genicity study in the rat includes an assessment of
chronic toxicity at 12 months, which allows for some
assessment of progression beyond 12 months and al-
lows the potential effects of aging to be taken into
account.
The proposed tiered testing approach has the potential to pro-
vide new information for risk assessment for shorter human ex-
posure durations while reducing the number of animals used
and without compromising the sensitivity of the determination
of longer-term RfDs. However, it is recognized that the approach
to date has been challenged with only a relatively limited num-
ber of compounds. It is anticipated that, once disseminated, the
approach will be further evaluated by the scientific community
using a wider range of compounds. The Task Force encourages
investigators engaged in such work to place the results of such
evaluations in the public domain.
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http://www.hesiglobal.org.
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APPENDIX: DESCRIPTION OF KEY SYSTEMIC
TOXICITY STUDIES
Proposed Design of the Core 28-Day Toxicity Study
in the Rat
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• The proposed 28-day rat study is the pivotal study
in the assessment of subchronic toxicity, and is used
to provide information on relevance to human ex-
posure durations from 1 day up to 6 months either
alone or in conjunction with the 90-day dog study. Im-
plicit in the study design is the need to identify sub-
tle changes, as well as expression of more significant
toxicity.
• Dose levels are selected taking into account the out-
come of range-finding studies, and are supported by
relevant ADME data.
• The numbers of experimental animals used for the main
study, satellite groups, and recovery phase are scientif-
ically based on power calculations. For example, and
as guidance, power calculations indicate that for liver
Summary of Study Specification—Core 28-Day Toxicity Study in the Rat
Groups: Main study one control and up to five test. Recovery groups for main study and satellite groups at all
dose levels.
Number of animals: Main study, recovery and neurotoxicity satellite—to be determined from relevant power calculations.
Analysis of diets: Achieved concentration at all dose levels and homogeneity and stability at high and low doses.
Dose administration: Continuous for 28 days for main study, satellite, and recovery groups.
Clinical observations: Daily detailed observations, days 1–29 main study, recovery and satellite animals; recovery and
satellite animals in weeks 5 and 6. Daily cage-side observations.
Body weights: All animals daily, days 1–29. Thereafter, satellite and recovery animals weekly: days 36 and 43.
Food consumption: Monitored continuously throughout the study.
Functional observational
battery:
All main study animals in week 4 (including landing foot splay, grip strength, and tail-flick) and
recovery animals in week 6.
Motor activity: All main study animals in week 4 and recovery animals in week 6.
Clinical pathology: Urine samples for clinical chemistry from main study animals during week 4 and from recovery
animals during week 6. Blood samples for hematology and clinical chemistry from all main study
and recovery animals at scheduled termination. Satellite groups not evaluated.
Pathology: Main study and recovery—guideline-specified tissues (based on OECD 407 [OECD, 1995] and U.S.
EPA OPPTS 870.3100 [U.S. EPA, 1998a]), and any macroscopic abnormalities submitted from all
rats. Guideline-specified organs weighed.
Neuropathology satellites—The following tissues will be taken from all rats sacrificed by
perfusion fixation and preserved in an appropriate fixative: brain, eye (with optic nerve and
retina),∗ spinal cord (including cervical and lumbar swellings), spinal nerve roots (dorsal and
ventral root fibers) at cervical swelling, spinal nerve roots (dorsal and ventral root fibers) at
lumbar swelling, dorsal root ganglia at cervical swelling, dorsal root ganglia at lumbar swelling,
proximal sciatic nerve,∗ proximal tibial nerve,∗ distal tibial nerve (tibial nerve calf muscle
branches),∗ and gastrocnemius muscle.∗ (∗= left for processing, right for store.)
Proposed Design of the Core 90-Day Toxicity
Study in the Dog
• The proposed 90-day dog study is pivotal in
the assessment of subchronic toxicity, and is
used to provide information on relevance to
human exposure durations from 1 day up to
6 months either alone or in conjunction with
the 28-day rat study.
growth, a minimum of six rats/sex/group (in a 28-day
study) are needed to detect a 10% increase in liver
weight, with a power of 80% and at the 5% significance
level. These numbers are consistent with the outcome
of other statistical methods used in study design, such
as the resource equation method of Mead (Mead, 1988).
According to this method, the errors of freedom (E) in
an experiment should lie between 10 and 20—any more
may involve the unnecessary use of animals; any fewer
may give unreliable results. E is defined (for a com-
pletely random design) as (total number of animals)
− (number of experimental groups). Therefore, for a
28-day study with four experimental groups using six
animals/sex/group, E = (24 − 4) = 20, which is within
acceptable limits.
• Dose levels and study design will be influenced by
the quantitative and qualitative outcome of the 28-day
study in the rat and by the outcome of a preliminary
study in the dog, and will be supported by relevant
ADME data. Satellite animals may be added to the
standard study design to assess specific effects (such
as neuropathology) if the need is indicated from the
outcome of preceding studies.
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Summary of Study Specification—Core 90-Day Toxicity Study in the Dog
Groups: One control and typically three test.
Number of animals: 6/sex/group.
Dose administration: Once daily for 90 days by capsule or diet.
Analysis of dose
preparations:
None in capsule (assumes neat test substance in capsule) or analysis of all batches of diet.
Clinical observations: Pen-side observations three times daily. Detailed observations weekly.
Veterinary examinations: Detailed clinical examination (including cardiac and pulmonary auscultation and body temperature)
of all dogs prestudy and prior to termination.
Body weights: Weekly (for 2 weeks prestudy), on day 1, and weekly thereafter.
Food consumption: Daily (for 2 weeks prestudy and throughout the study).
Ophthalmoscopy: All dogs prestudy and prior to termination.
Physiological
measurements:
Lead II electrocardiogram and direct blood pressure recorded from all dogs prestudy, and then prior
to and at one time point postdosing on day 1 and in weeks 7 and 13.
Toxicokinetics: Blood samples from all test group dogs at typically 6 time points after dosing on day 1 and in weeks
7 and 13.
Clinical pathology: Blood samples for hematology and clinical chemistry taken from all dogs prestudy and in week 13.
Urine samples (by catheterization) collected from all dogs prestudy and in week 13.
Pathology: Detailed examination post-mortem and tissues submitted from decedents and all animals at
termination. Selected organs weighed from all animals at scheduled termination. All
abnormalities, all submitted tissues from all animals processed and examined. (Based on OECD
409 [OECD, 1998] and U.S. EPA OPPTS 870.3150 [U.S. EPA, 1998b].)
Data evaluation: Relevant data will be analyzed statistically using relevant statistical approaches.
Report: Full quality-assured report with individual animal data supplement.
Proposed Design of the Single-Dose Toxicity Study
in the Rat/Dog
• The single-dose study is intended to provide data that
may be used to refine risk assessments relevant to hu-
man exposure durations of up to 1 day, as well as to in-
termittent exposures. The study design is based on that
proposed in setting an acute reference dose (Solecki,
2001).
• Dose levels and study design will be influenced by the
quantitative and qualitative outcome of the 28-day rat
study and 90-day dog study, and will be supported by
relevant ADME data.
• The numbers of experimental animals used for the
study are scientifically based on power calculations as
described for the 28-day rat study or, for the dog study,
six dogs/sex/dose level will be used.
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Summary of Study Specification—Single-Dose Toxicity Study in the Rat/Dog
Groups: One control and up to three test.
Number of animals: To be determined from relevant power calculations (see above); equal numbers of animals sacrificed
at 24 hours and at the end of the 14-day recovery phase.
Analysis of dosing
preparation:
Achieved concentration at all dose levels and homogeneity and stability at high and low doses
(gavage dosing).
Dose administration: Single dose by oral gavage (rat) or by capsule (dog).
Clinical observations: Daily detailed observations at time of peak effect and at 0.5, 1, 2, 4, and 24 hours after dosing; daily
thereafter.
Body weights: All animals daily for the first week, then prior to sacrifice of the recovery subgroup.
Food consumption: Monitored continuously throughout the study.
Functional observational
battery:
All animals at time of peak effect, prior to sacrifice at 24 hours, or after the recovery period.
Motor activity: All animals at time of peak effect, prior to sacrifice at 24 hours, or after the recovery period.
Clinical pathology: Urine samples for clinical chemistry from interim sacrifice animals and, if effects observed, again at
the end of the recovery period. Blood samples for hematology and clinical chemistry from all
animals at scheduled termination.
Pathology: Range of tissues weighed and examined histopathologically for all animals at scheduled
termination. Any macroscopic abnormalities submitted from all animals. Requirement based on
OECD 407 (OECD, 1995) and U.S. EPA OPPTS 870.3100 for the rat (U.S. EPA, 1998a), and
OECD 409 (OECD, 1998) and US EPA 870.3150 for the dog (U.S. EPA, 1998b).
Proposed Design of the 24-Month Combined Chronic
Toxicity/Carcinogenicity Study in the Rat
The 24-month combined chronic toxicity/carcinogenicity
study in the rat includes an assessment of chronic toxicity at
12 months. Conduct of this study (if indicated from the dura-
tion of human exposure) would lead to a waiver of the need
to conduct a separate 12-month chronic toxicity study in this
species.
Summary of Study Specification—24-Month Rat Combined Chronic Toxicity/Carcinogenicity Study
Groups: One control and up to five test.
Number of animals: 50 males and 50 females for the main study, plus 10 males and 10 females for interim sacrifice at 12
months.
Analysis of diets: Achieved concentration at all dose levels and homogeneity and stability at high and low doses.
Dose administration: Continuous in the diet for up to 24 months.
Clinical observations: Twice daily cage-side observations. Detailed observations recorded weekly—all study animals.
Ophthalmoscopy: All animals examined pre-study, and control and high dose for main study and recovery groups
examined prior to termination.
Body weights: All animals weekly pre-study and throughout the study.
Food consumption: Monitored continuously throughout the study.
Functional observational
battery:
Interim sacrifice animals in week 52, and main study animals in weeks 14, 27, 53, 79 and prior to
termination.
Motor activity: Interim sacrifice animals in week 52, and main study animals in weeks 14, 27, 53, 79 and prior to
termination.
Clinical pathology: Urine samples for clinical chemistry from main study animals in weeks 14, 27, 53, 79 and at
termination. Blood samples for hematology and clinical chemistry from all main study animals in
weeks 14, 27, 53, 79 and at termination.
Pathology: All animals, guideline-specified tissues (based on OECD 453 [OECD, 1981] and U.S. EPA OPPTS
870.4300 [U.S. EPA, 1998d]) and any macroscopic abnormalities submitted from all rats.
Guideline-specified organs weighed.
